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7ABSTRACT
The aim of the present study was to investigate the effects of treating experimental
colitis by modulating colonic microbiota and eicosanoids, more specifically, the
effects of Lactobacillus rhamnosus GG, Lactobacillus reuteri R2LC, two galacto-
oligosaccharide mixtures and the cys-LT-1 receptor antagonist montelukast in
chemically induced colitis in rats.
L. rhamnosus GG increased the number of caecal and colonic crypt cells as well as
the rate of mitoses in the caecal crypts, and decreased the depth of the crypts, when
given orally to healthy germ-free rats for 3 or 21 days. In spite of these potentially
beneficial effects on intestinal inflammation, L. rhamnosus GG, as well as L. reuteri
R2LC, when given orally beginning seven days before colitis induction, were
ineffective in the attenuation of acetic acid-induced colitis, as was the reference drug
sulphasalazine. The oral administration of galacto-oligosaccharides, starting 10 days
before the induction of colitis, stimulated the growth of bifidobacteria, but neither they
nor the reference drug dexamethasone affected acute colitis induced by
trinitrobenzene sulphonic acid (TNBS).
Animals with acute colitis induced by TNBS, when treated with the cys-LT-1 receptor
antagonist montelukast (5−20 mg kg-1 day-1, intracolonically, starting 12 hours before
colitis induction), had an increased colonic in vitro production of prostaglandin E2, an
eicosanoid beneficial in the treatment of colonic inflammation in a TNBS model and a
number of other models. However, montelukast, as well as the reference drug
zileuton, a 5-lipoxygenase inhibitor, did not ameliorate macroscopic and histological
inflammation in the colon in this acute severe model. On the other hand, in a milder
colitis model, the dextran sulphate sodium (DSS) model, animals treated with
montelukast (10 mg kg-1 day-1, p.o., starting concurrently with DSS) had less occult
blood in the faeces/ gross bleeding and normal body weight gain. They also tended
to have a lower ratio of leukotriene B4/ prostaglandin E2 production in the colon in
vitro. No increase in the production of cysteinyl leukotrienes in vitro was detected in
either of the colitis models.
The models used in the present study for investigating the effects of modulating
microbiota appear severe because the reference drugs were ineffective. Neither the
beneficial effects of L. rhamnosus GG seen in this study, both on the rate of mitoses
and on the morphology of the mucosa, nor the hypothesised mechanisms (i.e. the
production of antimicrobial products, the decrease in intestinal permeability, the
8promotion of gut immunoglobulin A response, and the increase in short-chain fatty
acid concentration in the case of galacto-oligosaccharides) seem to be sufficient to
deal with the acute phase of these severe colitis models.
The cys-LT-1 receptor antagonist montelukast slightly ameliorated the mild colitis
induced with DSS, but not the severe acute TNBS-induced colitis. The fact that the
former was not associated with increased cysteinyl leukotriene production suggests
that some other mechanism than cys-LT-1 receptor blockade is responsible for the
colitis-attenuating effect.
Theoretically, L. rhamnosus GG, L. reuteri R2LC, galacto-oligosaccharides and
montelukast all have the potential to attenuate colonic inflammation. They are not,
however, efficient in reducing the damage in acute severe models such as those
used in the present study.
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1 INTRODUCTION
Experimental models of colitis imitate the human inflammatory bowel diseases (IBD),
ulcerative colitis and Crohn’s disease, chronic relapsing diseases of unknown
aetiology (for reviews, see Sartor 1997a, Fiocchi 1998). Unlike ulcerative colitis,
Crohn’s disease can appear anywhere in the gastrointestinal tract (for review, see
Friend 1998). In 30−40% of cases the colon is significantly affected. In ulcerative
colitis, the inflammation in the colonic mucosa is evenly distributed, and is primarily
limited to the mucosa (for review, see Hendrickson et al. 2002). In Crohn’s disease,
on the other hand, the inflammation is transmural and patchy. The main symptoms of
IBD are diarrhoea, the presence of blood in the faeces, abdominal pain, fever and
weight loss. Extraintestinal complications, such as arthritis, and mucocutaneous,
ophthalmologic and hepatobiliary lesions, are frequent. IBD is medically incurable,
and its treatment is targeted at reducing the inflammatory reaction and symptoms,
and consists of inducing remission of the active disease and then maintaining
remission to prevent relapse (for review, see Hanauer & Dassapoulos 2001).
There is a growing body of evidence to support the role of intestinal microbiota in the
initiation and progression of IBD (for review, see Linskens et al. 2001). A variety of
specific pathogens have been proposed as aetiological factors, but studies have
shown conflicting results and no aetiological agent has yet been convincingly
identified. Although some alterations in the colonic microbiota in IBD as well as in
experimental colitis models have been reported, no consistent changes in the
composition of the intestinal microbiota have been found. However, lactobacilli have
been reported to be reduced in these diseases in several studies in both man and
animals (Giaffer et al. 1991, Hartley et al. 1992, Fabia et al. 1993a, Videla et al.
1994, Madsen et al. 2000).
Antimicrobial agents have proved effective in experimental colitis models and in
Crohn’s disease (Onderdonk et al. 1978, Ursing et al. 1982, Sutherland et al. 1991,
Prantera et al. 1994, Videla et al. 1994, Rutgeerts et al. 1995, Prantera et al. 1996,
Panwala et al. 1998, Hans et al. 2000, Madsen et al. 2000, Rath et al. 2001),
whereas results obtained in ulcerative colitis are much less consistent (Dickinson et
al. 1985, Chapman et al. 1986, Burke et al. 1990, Mantzaris et al. 1997, Turunen et
al. 1998). In addition, there are studies which show that experimental colitis clearly
benefits from other methods of modifying the intestinal microbiota: both by probiotics,
defined by Fuller (1989) as “live microbial feed supplements which beneficially affect
the host animal by improving its intestinal microbial balance” (Fabia et al. 1993b,
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Mao et al. 1996, Madsen et al. 1999, Madsen et al. 2001, O’Mahoney et al. 2001,
Schultz et al. 2002), and by prebiotics, defined by Gibson & Roberfroid (1995) as
“nondigestible food ingredients that beneficially affect the host by selectively
stimulating the growth and/or activity of one or a limited number of beneficial bacteria
such as lactobacilli and bifidobacteria in the colon, and thus improve host health”
(Madsen et al. 1999, Videla et al. 2001).
The formation of leukotrienes is enhanced in the intestinal mucosa in IBD (for review,
see Eberhart & Dubois 1995). Leukotriene B4 (LTB4) is apparently the main
chemoattractant for neutrophils in an inflamed mucosa, stimulating adhesion,
chemotactic movement, aggregation, enzyme release, the generation of superoxide,
and the exudation of plasma (for review, see Samuelsson et al. 1987). The data
support the direct involvement of LTB4 in the pathophysiology of IBD (for review, see
Eberhart & Dubois 1995). Cysteinyl leukotrienes contract smooth muscle, cause the
leakage of plasma, stimulate mucus secretion and recruit eosinophils (for reviews,
see Samuelsson et al. 1987, Dahlén 1997). It is only recently that the potent
proinflammatory activities of cysteinyl leukotrienes have attracted greater attention
(for review, see Sala & Folco 2001), but their role in IBD has not been clarified.
Whereas experimental colitis benefits from 5-lipoxygenase inhibition (Wallace et al.
1989, Woolverton et al. 1989, Wallace & Keenan et al. 1990, Empey et al. 1992,
Zingarelli et al. 1993, Bertrán et al. 1996, Zarif et al. 1996), clinical trials have
produced disappointing results (Laursen et al. 1994, Hawkey et al. 1997, Roberts et
al. 1997). Only a few experimental studies exist on cys-LT-1 receptor antagonists in
experimental colitis (Pons et al. 1992, Morteau et al. 1993, Nishikawa et al. 1995),
and to my knowledge no clinical trials have been conducted.
Prostaglandin production is increased in the colon in IBD (for review, see Eberhart &
Dubois 1995). Prostaglandins have a pro-inflammatory capacity: they enhance local
vasodilatation and subsequent oedema formation, and may account for the
associated diarrhoea (for review, see Whittle and Vane 1987). However,
prostaglandins seem to have physiological functions in the gastrointestinal tract, and
certain prostaglandins are anti-inflammatory, suppressing various cellular immune
functions, accelerating cell production and differentiation after mucosal damage,
stimulating mucus production, and modulating local blood flow (for reviews, see
Whittle and Vane 1987, Eberhart & Dubois 1995). In fact, exogenous prostaglandins
have been shown to ameliorate intestinal damage in experimental models of colitis
(Wallace et al. 1985, Psaila et al. 1986, Allgayer et al. 1989, Fedorak et al. 1990,
Yamada et al. 1991, 1992, Empey et al. 1992, Torsher et al	
et al.
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1997, Onizuka et al. 2000, Sasaki et al. 2000), whereas non-steroidal anti-
inflammatory drugs (NSAID) seem to exacerbate the disease (Empey et al. 1992,
Wallace et al. 1992, LeDuc et al. 1993, Reuter et al. 1996, Kabashima et al. 2002).
The aim of the present study was to investigate the effects of the treatment of
experimental colitis by modulating colonic microbiota and eicosanoids. More
specifically, the effects of Lactobacillus rhamnosus GG, Lactobacillus reuteri R2LC,
two galacto-oligosaccharide mixtures and the cys-LT-1 receptor antagonist
montelukast in colitis in rats, were studied.
Review of the literature
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2 REVIEW OF THE LITERATURE
2.1 EXPERIMENTAL COLITIS MODELS
Numerous experimental colitis models for human IBD have been developed. They
are based either on chemical induction, immune cell transfer or gene targeting (Table
I) (for reviews, see Kim & Berstad 1992, Elson et al. 1995, Boismenu & Chen 2000,
Pizarro et al. 2000). In addition, colitis develops spontaneously in three naturally
occurring animal species, the cotton-top tamarin, the rhesus macaque and a mouse
strain C3H/HeBir. These three represent the most attractive models, because the
disease occurs without any apparent exogenous manipulation, very much as it does
in humans. However, the cotton-top tamarin and the rhesus macaque are not widely
available, limiting their use as research tools.
The most widely used models are based on chemical induction. In these models the
irritant is administered either by luminal instillation [acetic acid, trinitrobenzene
sulphonic acid (TNBS), a formalin-immune complex, oxazolone,
dinitrochlorobenzene (DNCB), iodoacetamide], in drinking water [dextran sulphate
sodium (DSS), carrageenan], by gastric gavage (cyclosporin A), or by intramural
injection into multiple sites [peptidoglycan-polysaccharide (PG-PS)] (for reviews, see
Kim & Berstad 1992, Elson et al. 1995; Rachmilewitz et al. 1995, Boirivant et al.
1998). In a formalin-immune complex model, the luminal instillation of formalin is
preceded by intravenous injection of pre-formed immune complexes (for review, see
Elson et al. 1995). In TNBS and oxazolone models, irritants are administered in a
“barrier breaker”, ethanol, allowing the penetration of the haptens TNBS and
oxazolone into the tissues (for review, see Elson et al. 1995; Boirivant et al. 1998).
DNCB is also a haptenating agent, but, in contrast to TNBS and oxazolone, in order
to induce colitis the animals have to be sensitised to the agent before it is installed
luminally (for review, see Kim & Berstad 1992). Continuous administration of DSS or
carrageenan in drinking water induces colonic inflammation within about a week (for
review, see Elson et al. 1995). Inducing colitis by cyclosporin A includes the
depletion of mature T cells from bone marrow before transfer into irradiated
recipients and treatment with cyclosporin A by gastric gavage over a period of
several weeks.
Most of the chemically induced models are acute colitis models (for review, see
Elson et al. 1995) (Table I). However, some of them have chronic characteristics as
well. If administered several times, TNBS induces chronic colitis, which can also be
induced if DSS is administered in cycles of alternating DSS and water. PG-PS
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induces chronic colitis in susceptible strains. Carrageenan and cyclosporin A can
also induce chronic inflammation in the colon.
In immune cell transfer models, T cells or bone marrow precursors are introduced
into immunodeficient recipients (for review, see Pizarro et al. 2000). The transfer of a
subset of normal CD4+ T cells (i.e. CD4+ T cells expressing high levels of the surface
molecule CD45RB) into mice deficient in B and T cells, results in colitis (for review,
see Elson et al. 1995). In a bone marrow chimera transfer model, colitis is induced in
mice with an arrest in very early T cell development by the transplantation of T cell
depleted bone marrow (Holländer et al. 1995).
Colitis can also be induced by gene targeting i.e. by knocking out or transferring
certain genes (for review, see Elson et al. 1995). Knockout models include
interleukin (IL) -2, IL-10, Gαi2, and multiple drug resistance gene mdr1a knockout
mice, and αβ T cell and keratin 8 deficient mice (Table I). IL-2 and IL-10 are
important regulatory cytokines, the former promoting the growth and expansion of T
cells, the differentiation of B cells and the activation of macrophages, the latter
inhibiting macrophages and type 1 helper T cells. Gαi2 is a subunit of G protein widely
distributed in cells, including gut epithelial cells and lymphoid cells, and forms part of
the protein complex that regulates signal transduction through adenylate cyclase.
The role of the products of mdr1a has not been fully elucidated, but they are known
to be expressed in many tissues including intestinal epithelial cells, and to pump
toxic drugs out of cells (Panwala et al. 1998). Keratin 8 targeted mutation prevents
the formation of extended keratin filaments in many tissues including the
gastrointestinal tract (Baribault et al. 1994). Transgenic models include T cell
receptor transgenic mice. There are also several gene-manipulated models in which
colitis develops in conjunction with numerous pathological alterations in other organs
(for review, see MacDonald et al. 2000).
Despite the number of available experimental colitis models, no animal models exist
that resemble human IBD in every aspect. However, when chosen appropriately,
they can be used to explore pathophysiological mechanisms and develop
hypotheses, and they are important in testing emerging therapeutic alternatives in
the pre-clinical phase. The relevance of experimental colitis models to human IBD
can be summarized as follows: the mucosal inflammation of genetically-engineered,
DSS and formalin-immune complex-mediated models more closely resemble
ulcerative colitis, whereas the transmural damage induced by PG-PS and TNBS is
more relevant to Crohn’s disease (for review, see Sartor 1997b).
Table I. Experimental colitis models.
      Carrageenan Caecum > left colon Acute > chronic UC Epithelial injury Watt & Marcus 1969
      Acetic acid Left colon, rectum Acute UC Non-specific following barrier injury MacPherson & Pfeiffer 1978
      Formalin-immune complex Distal colon Acute UC Complement activation, IL-1 ↑ Hodgson et al. 1978
      DNCB Colon Acute UC Hapten Rabin & Rogers 1978
      TNBS Colon Acute, chronic CD Hapten + barrier breaker (ethanol) Morris et al. 1989
      DSS Left > right colon Acute, chronic UC Epithelial injury Okayasu et al. 1990
      PG-PS Ileum, caecum, left colon Acute, chronic CD Macrophage activation, IL-1 ↑ Yamada et al. 1993
      Cyclosporin A Colon Acute, chronic T cell mediated Bucy et al. 1993
      Iodoacetamide Colon Acute Sulfhydryl blockade Rachmilewitz et al. 1995
      Oxazolone Left colon Acute, chronic UC Hapten + barrier breaker (ethanol) Boirivant et al. 1998
Immune cell transfer
      CD45RBhigh transfer model Colon > ileum Chronic > acute CD CD4+ T cells → regulatory imbalance Morrissey et al. 1993
      Bone marrow chimera transfer Colon Acute, chronic UC Lack of thymic selection Holländer et al. 1995
Transgenic/ knockout
      IL-2 knockout Left > right colon Acute, chronic UC IL-2 ↓ → regulatory imbalance Sadlack et al. 1993
      IL-10 knockout Small intestine, colon Chronic UC IL-10 ↓ → regulatory imbalance Kühn et al. 1993
      αβ T cell deficient Colon Acute, chronic UC Lack of αβ T cells, autoantibodies Mombaerts et al. 1993
      Keratin 8 deficient Colon Chronic - Baribault et al. 1994
      Gαi2 knockout Left > right colon Chronic > acute UC Abnormal thymic development Rudolph et al. 1995
      mdr1a knockout Colon Chronic UC Panwala et al. 1998
      T cell receptor transgenic Colon Chronic UC Koh et al. 1999
Spontaneous
      Cotton-top tamarin Colon Chronic > acute UC Madara et al. 1985
      C3H/HeJBir mouse Caecum, right colon Acute, chronic - Sundberg et al. 1994
      Rhesus macaque Caecum, colon, rectum Chronic UC Ribbons et al. 1995
Modified from Elson et al. 1995, Fiocchi 1998, Boismenu & Chen 2000. DNCB, dinitrochlorobenzene; TNBS, trinitrobenzene sulphonic acid; DSS, dextran sulphate sodium;
PG-PS, peptidoglycan-polysaccharide; Gαi2, G protein subunit αi2; mdr1a, multiple drug resistance gene; UC, ulcerative colitis; CD, Crohn’s disease.
Model Area involved Inflammation Clinical
similarity
Possible pathogenic mechanism Reference
Chemically induced
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2.2 ROLE OF COLONIC MICROBIOTA IN COLITIS
2.2.1 Rationale for affecting microbiota
There is evidence to support the role of intestinal microbiota in the initiation and
progression of IBD. The colon and distal small intestine, the parts of the
gastrointestinal tract that are most commonly involved in IBD, contain the largest
number of micro-organisms (for reviews, see Sartor 1998, Linskens et al. 2001).
In several experimental models of IBD, intestinal inflammation either does not
develop or is much less severe in animals raised in germ-free conditions (for review,
see Sartor 1997c; Rath et al. 1996, Dianda et al. 1997, Sellon et al. 1998). More
direct evidence to support the importance of microbiota is provided by experimental
studies where bacterial products, such as PG-PS polymers, can induce and
aggravate colitis (for review, see Sartor 1997c; Yamada et al. 1993).
Based on serological responses or on the presence of organisms or specific antigens
in affected tissues, a variety of specific pathogens have been proposed as aetiologic
agents for IBD, such as Mycobacterium paratuberculosis, Listeria monocytogenes,
paramyxovirus, Chlamydia trachomatis and Escherichia coli, but studies have
produced conflicting results, and no aetiological agent has yet been convincingly
identified (for review, see Linskens et al. 2001).
Earlier investigations using culturing as the method for enumerating bacteria,
reported normal levels of mucosa-associated microbial flora in Crohn’s disease
(Peach et al. 1978) and decreased levels in ulcerative colitis, especially in total
anaerobes, including gram-negative anaerobes and lactobacilli (Hartley et al. 1992,
Fabia et al. 1993a). More recent studies, in contrast, using in situ hybridisation and
polymerase chain reaction techniques, alone or in combination with culturing, have
demonstrated that both Crohn’s disease and ulcerative colitis are associated with
high numbers of mucosal bacteria (Schultsz et al. 1999, Swidsinski et al. 2002), and
that the concentration of the bacteria increases progressively with the severity of the
disease (Swidsinski et al. 2002). However, there seems to be no principal difference
in the composition of the mucosal flora in inflammatory bowel disease compared to
controls (Swidsinski et al. 2002).
The faecal microbiota in ulcerative colitis has been reported to be similar to that of
healthy controls, both qualitatively and quantitatively (Cooke 1967, Gorbach et al.
1968, Keighley et al. 1978, Giaffer et al. 1991), apart from an increase in coliforms in
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the case of the severe disease (Gorbach et al. 1968). Such a change, however, is
generally regarded as a non-specific effect of any condition associated with
diarrhoea. It has been suggested that the faecal flora in Crohn’s disease may contain
high numbers of Escherichia coli, total aerobes (Giaffer et al. 1991) and anaerobic
gram-positive coccoid rods and gram-negative rods (Wensinck et al. 1981, Ruseler-
van Embden & Both-Patoir 1983). The presence of these gram-negative rods
appears to be due to the Bacteroides fragilis group, in particular to Bacteroides
vulgatus, which is a member of this group (Ruseler-van Embden & Both-Patoir
1983). However, decreased levels of faecal lactobacilli and bifidobacteria in Crohn’s
disease have been reported (Giaffer et al. 1991, Favier et al. 1997).
Different experimental models have also been described as being associated with
alterations in intestinal microbiota. Carrageenan administration is associated with a
substantial increase in coliform counts (Onderdonk et al. 1978), but, as noted above,
such a change is generally regarded as a non-specific effect of conditions associated
with diarrhoea. An acetic acid model results in decreased levels of mucosa-
associated total anaerobes, including gram-negative anaerobes and lactic acid
bacteria (Fabia et al. 1993a). A TNBS model is associated with the absence of
Lactobacillus bacteria and an increase in other aerobic isolates such as Escherichia
coli and Staphylococcus spp. (Videla et al. 1994). IL-10 gene-deficient mice that
develop colitis by the age of four weeks have reduced levels of colonic Lactobacillus,
Staphylococcus and Enterococcus, but increased levels of Streptococcus and
Clostridium, before any histological colonic injury is seen (Madsen et al. 2000). In
these mice, total colonic bacterial levels are lower than in normal mice, but there is
an increase in the bacteria either adherent or translocated to the colonic mucosa.
Once the colonic injury has developed, these changes dissipate, except for the
increase in adherent or translocated bacteria, which persists.
To sum up, the intestinal microbiota has a role in IBD in both animals and man.
Apparently the mucosa-associated microbes are more closely related to the
inflammatory process than the faecal microbiota. Although not a consistent finding in
all studies, lactobacilli have been described in several reports as being reduced in
both animals and man. In contrast, the levels of Bacteroides appear to increase in
these diseases. In spite of these observations, no consistent alterations in the
composition of the intestinal microbiota have been found.
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2.2.2 Antimicrobial treatment
Experimental studies
Preventive strategies using various antimicrobial agents have had favourable effects
on experimental colitis (Table II). Metronidazole, an antimicrobial agent against
anaerobes and parasites, has proved effective in the prevention of colitis in various
models (Onderdonk et al. 1978, Rath et al. 2001, Fukuda et al. 2002). Combining
metronidazole with ciprofloxacin, which eliminates aerobic gram-negative bacteria, or
with neomycin, which is effective against anaerobes, has also demonstrated
beneficial effects in the prevention of experimental colitis (Hans et al. 2000, Madsen
et al. 2000). Other antimicrobial agents with preventive effects on experimental colitis
include ciprofloxacin (Madsen et al. 2000, Rath et al. 2001) and vancomycin alone
(Fukuda et al. 2002), and the broad spectrum antibiotic combinations of vancomycin
and imipenem (Videla et al. 1994, Rath et al. 2001), amoxicillin and clavulanic acid
(Videla et al. 1994) and streptomycin, neomycin, bacitracin and amphotericin
(Panwala et al. 1998). However, various other antimicrobial agents have failed to
show any preventive effects in experimental colitis models (Onderdonk et al. 1978,
Videla et al. 1994) (Table II).
Treatment of established experimental colitis with different antimicrobial agents has
only rarely proved beneficial (Table II). Although effective in the prevention of colitis
in different models, metronidazole is not sufficient as a treatment on its own in
established experimental colitis (Onderdonk et al. 1978, Rath et al. 2001). The same
applies to the combination of metronidazole and ciprofloxacin (Hans et al. 2000).
However, when combined with neomycin, metronidazole can effectively treat
experimental colitis (Madsen et al. 2000). Ciprofloxacin alone has not been shown to
treat colitis effectively in every model investigated (Madsen et al. 2000, Rath et al.
2001). A combination of vancomycin and imipenem has shown favourable effects in
several models (Videla et al. 1994, Rath et al. 2001). Numerous other antimicrobial
agents have failed to treat experimental colitis (Gardiner et al. 1994, Videla et al.
1994).
Overall, antimicrobial agents have proved much more effective in preventive
protocols than in treatment protocols in experimental colitis models. In contrast to
selective antimicrobes, metronidazole, ciprofloxacin and different broad spectrum
antimicrobial combinations seem to be able to prevent the establishment of colitis,
underlining the importance of anaerobes, gram-negative species and normal colonic
Table II. Antimicrobial drugs used in experimental colitis.
*In drinking water. HLA-B27 transgenic rat, rat with a multiorgan disease resembling human spondyarthropathies (for review, see Elson et al. 1995).
Drugs Model Results Reference
Metronidazole (2 mg ml-1 p.o.)*
Gentamicin (2 mg ml-1 p.o.)*
Sulfamethoxazole-trimethoprim (3 mg ml-1 p.o.)*
Carrageenan Prevention: only metronidazole effective
Treatment: metronidazole ineffective (other
drugs not studied)
Onderdonk et al.
1978
Neomycin (30 mg day-1 p.o.)
Paromomycin (10 mg day-1 p.o.)
Polymyxin (250 i.u. i.v.)
Taurolidine (35 mg i.v.)
Cefuroxime (35 mg) + metronidazole (7.5 mg) (i.v.)
TNBS Treatment: all drugs ineffective, polymyxin
worsened condition
Prevention: not studied
Gardiner et al.
1994
Amoxicillin (160 mg kg-1 day-1) + clavulanic acid (40 mg kg-1 day-1) (enema)
Tobramycin (2 mg kg-1 day-1) + vancomycin (50 mg kg-1 day-1) (enema)
Tobramycin (2 mg kg-1 day-1 enema)
Metronidazole (20 mg kg-1 day-1 enema)
Imipenem + vancomycin (50 mg kg-1 day-1 both) (enema, i.p. or p.o.)
Vancomycin (50 mg kg-1 day-1 p.o.)
Imipenem (50 mg kg-1 day-1 p.o.)
TNBS Prevention: only imipenem + vancomycin
and amoxicillin + clavulanic acid effective,
affecting both acute and chronic colitis,
(i.p. imipenem + vancomycin ineffective)
Treatment: only imipenem + vancomycin
effective
Videla et al.
1994
Streptomycin (1.25% w/v) + neomycin (1% w/v) +
bacitracin (1% w/v) + amphotericin (0.25% w/v) (p.o.)*
mdr1a gene-
deficient mouse
Prevention; combination effective
Treatment: combination effective
Panwala et al.
1998
Metronidazole (1 mg day-1) + ciprofloxacin (0.5 mg day-1) (i.p.) DSS Prevention: combination effective
Treatment: combination ineffective
Hans et al. 2000
Ciprofloxacin (40 mg kg-1 day-1 p.o.)
Neomycin (90 mg kg-1 day-1) + metronidazole (150 mg kg-1 day-1) (p.o.)
IL-10 gene-
deficient mouse
Prevention: both drugs effective
Treatment: both drugs effective
Madsen et al.
2000
Metronidazole (40 mg kg-1 day-1 p.o.)
Ciprofloxacin (50 mg kg-1 day-1 p.o.)
Vancomycin + imipenem (50 mg kg-1 day-1 both) (p.o.)
DSS,
HLA-B27
transgenic rat
Prevention: drugs effective in both models,
(ciprofloxacin in DSS model was not
evaluated)
Treatment: only vancomycin + imipenem
effective
Rath et al. 2001
Metronidazole (20 mg kg-1 day-1 p.o.)
Vancomycin (50 mg kg-1 day-1 p.o.)
DSS Prevention: both drugs effective Fukuda et al.
2002
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microbiota. Only some broad spectrum antimicrobial combinations seem to be
effective in the treatment of established experimental colitis. It has been suggested
that the mechanism of antimicrobials may be associated with decreased levels of
mucosal adherent and translocated bacteria (Madsen et al. 2000).
Clinical trials
The double-blind clinical trials conducted with antimicrobial agents in Crohn’s
disease are presented in Table III. Only metronidazole has consistently been seen to
ameliorate active Crohn’s disease (Ursing et al. 1982, Sutherland et al. 1991).
Metronidazole has also reduced the severity of the early recurrence of Crohn’s
disease after ileal resection (Rutgeerts et al. 1995), and a combination of
metronidazole and ciprofloxacin has shown comparable results to steroids in treating
active Crohn’s disease (Prantera et al. 1996). Most of the results obtained with
antimycobacterial therapy are negative (Afdhal et al. 1991, Prantera et al. 1994, Swift
et al. 1994, Goodgame et al. 2001).
Whereas Crohn’s disease patients seem to benefit from metronidazole, the drug has
shown disappointing results as an adjunct to corticosteroids in the treatment of acute,
severe ulcerative colitis (Chapman et al. 1986) (Table IV). Oral tobramycin, as an
adjunct to steroids, has shown beneficial effects in the short term in patients with
acute ulcerative colitis (Burke et al. 1990). Oral ciprofloxacin, combined to the
standard treatment, has been ineffective as a short course therapy in active
ulcerative colitis (Mantzaris et al. 1997), but effective as a long-term treatment
(Turunen et al. 1998). Finally, vancomycin has been reported as being ineffective as
an adjunct to steroids in acute exacerbations of ulcerative colitis (Dickinson et al.
1985).
To sum up, the data support the use of antimicrobial agents in the treatment of
Crohn’s disease, whereas convincing evidence of their efficacy in the treatment of
ulcerative colitis is lacking. Although antimicrobial agents have shown favourable
effects in the treatment of Crohn’s disease, the changes in the microbiota
responsible are not known. In fact, there are no clinical trials linking the beneficial
effects of antimicrobial agents to quantitative changes in the microbiota. Therefore,
effects other than the antimicrobial activity of these agents should also be kept in
mind − for example, metronidazole and ciprofloxacin may possess some
immunosuppressive activity.
Table III. Double-blind clinical trials using antimicrobial agents in Crohn’s disease.
Drugs Patients Length of the
study
Results Reference
Metronidazole (400 mg b.i.d. p.o.)
          vs. sulphasalazine (1.5 g b.i.d. p.o.)
78 with active disease 8 months Metronidazole slightly more
effective than sulphasalazine
Ursing et al.
1982
Remission induction: Clofazimine (100 mg day-1 p.o.) +
steroids
Maintenance: Clofazimine (100 mg day-1 p.o.)
49 with active disease Remission
induction: 0−3
months
Maintenance:
4−12 months
Ineffective Afdhal et al.
1991
Metronidazole (10 or 20 mg kg-1 day-1, dispensed in three
daily doses p.o.)
105 with active
disease
16 weeks Effective Sutherland et
al. 1991
Ethambutol (15 mg kg-1 day-1 p.o.) + clofazimine (100
mg every 2 days p.o.) + dapsone (100 mg for 6 days per
week p.o.) + 1-day dose only of rifampicin (600 mg p.o.)+
tapering steroids for first 8 weeks
40 with active disease 9 months Effective in maintenance of
remission
Prantera et al.
1994
Rifampicin (450−600 mg day-1 p.o.) + ethambutol (15
mg kg-1 day-1 p.o.) + isoniazid (300 mg day-1 p.o.);
(Continuation of all other drugs considered appropriate.)
130 with active
disease
2 years Ineffective Swift et al.
1994
Metronidazole (20 mg kg-1 day-1, dispensed in three daily
doses p.o.)
60 with curative ileal
resection and primary
anastomosis
3 months, 3-year
follow-up
Reduced the severity of early
recurrence after ileal resection
Rutgeerts et
al. 1995
Metronidazole (250 mg 4 times daily p.o.) +
ciprofloxacin (500 mg b.i.d. p.o.) vs. tapering steroids
41 with active disease 12 weeks Effect comparable to steroids Prantera et al.
1996
Clarithromycin (500 mg b.i.d. p.o.) + ethambutol (15 mg
kg-1 day-1 p.o.) as an adjunct to standard therapy
31 at high risk of
relapse
3 months, 1-year
follow-up
Ineffective Goodgame et
al. 2001
Table IV. Double-blind clinical trials using antimicrobial agents in ulcerative colitis.
Drugs Patients Length of the
study
Results Reference
Vancomycin (500 mg every 6 hours p.o.) as an adjunct to
steroids
40 with acute
exacerbations (33
ulcerative colitis, 7
Crohn’s disease)
7 days Ineffective Dickinson et
al. 1985
Metronidazole (500 mg every 8 hours i.v.) as an adjunct
to steroids
39 with acute, severe
disease
5 days Ineffective Chapman et
al. 1986
Tobramycin (120 mg t.i.d. p.o.) as an adjunct to steroids 84 with acute relapse 7 days, follow-up
for 21 or 28 days
Effective Burke et al.
1990
Ciprofloxacin (250 mg b.i.d. p.o.) as an adjunct to
steroids and olsalazine
70 with mild to
moderately active
disease
14 days, follow-up
for 7−9 weeks
Ineffective Mantzaris et
al. 1997
Ciprofloxacin (500−750 b.i.d. p.o.) as an adjunct to
steroids and mesalamine
83 with moderate to
severe disease activity
6 months,
6-month follow-up
Effective Turunen et al.
1998
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2.2.3 Probiotic and prebiotic treatment
Overview of probiotics and prebiotics
A probiotic is “a live microbial feed supplement which beneficially affects the host
animal by improving its intestinal microbial balance” (for review, see Fuller 1989).
Probiotics are mainly lactic acid bacteria, i.e. gram-positive bacteria which ferment
carbohydrates and produce lactic acid as the major end product (for review, see
Axelsson 1998). Lactobacillus in particular, but also Streptococcus, Lactococcus,
Leuconostoc, Enterococcus and Pediococcus, have been used as probiotics (for
review, see O’Sullivan et al. 1992). In addition, organisms other than lactic acid
bacteria, such as Bifidobacterium, Propionibacterium, Escherichia coli and yeast
Saccharomyces, have been used.
A prebiotic is “a nondigestible food ingredient that beneficially affects the host by
selectively stimulating the growth and/or activity of one or a limited number of
beneficial bacteria such as lactobacilli and bifidobacteria in the colon, and thus
improves host health” (for review, see Gibson & Roberfroid 1995). Nondigestible
carbohydrates (oligo- and polysaccharides), some peptides and proteins, and certain
lipids (both ethers and esters) are candidate prebiotics. However, for most of these
substances, the process of colonic fermentation is more or less non-specific.
Nondigestible oligosaccharides in general, and fructo-oligosaccharides in particular,
are prebiotics, stimulating bifidobacteria selectively. They also increase caecal short-
chain fatty acid concentration and reduce caecal pH.
Possible mechanisms of probiotic and prebiotic action
The mechanisms whereby probiotics exert their effects in general, and in IBD in
particular, are not fully understood (for review, see Alvarez-Olmos & Oberhelman
2001). Several mechanisms have been postulated. Lactic acid bacteria and
bifidobacteria produce general antimicrobial substances, such as organic acids,
hydrogen peroxide, carbon dioxide and diacetyl (for reviews, see Ballongue 1998,
Ouwehand 1998). Some strains also release specific low molecular weight
antimicrobial substances. In addition to these broad spectrum antimicrobial
compounds, many strains of lactic acid bacteria have been found to produce protein
and peptide bacteriocins with a more defined antimicrobial spectrum. L. rhamnosus
GG and L. reuteri secrete in vitro a low-molecular-weight antimicrobial substance
inhibitory to a broad spectrum of potential pathogens (Silva et al. 1987, Axelsson et
al. 1989). It has been suggested that several strains of bifidobacteria excrete an
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antimicrobial substance with inhibitory activity towards pathogens as well (Gibson &
Wang 1994). L. fermentum RC-14 releases components which can inhibit the
adhesion of a uropathogen Enterococcus faecalis 1131 in vitro (Heinemann et al.
2000). Saccharomyces boulardii degrades Clostridium difficile toxin receptors in the
rabbit ileum (Pothoulakis et al. 1993). Another mechanism against harmful species is
the fact that microbes compete with each other for a limited number of adhesion sites
on the epithelium (for review, see Alvarez-Olmos & Oberhelman 2001). Finally, some
probiotic bacteria are capable of normalizing increased intestinal permeability to
potentially antigenic macromolecules (Isolauri et al. 1993, Madsen et al. 2001).
Probiotics can modify the immune functions of the host, although the specific
mechanisms remain unclear (for review, see Erickson & Hubbard 2000). Enhanced
intestinal immunoglobulin (Ig) A production, which provides defence for the mucosal
surface (for review, see Doe 1989), has been reported in connection with the
administration of L. rhamnosus GG in Crohn’s disease (Malin et al. 1996), with L.
casei (Perdigón et al. 1991) and with Bifidobacterium bifidus (for review, see
Erickson & Hubbard 2000). The effect of probiotics on increased systemic IgA levels
has also been described, whereas there are reports of decreased systemic IgE levels
after probiotic ingestion (for review, see Erickson & Hubbard 2000). Enhanced
phagocytosis, which could be crucial in the eradication of pathogens, has been
described after administration of L. casei and L. bulgaricus (Perdigon et al. 1986) as
well as of L. rhamnosus GG (Pelto et al. 1998). It has also been suggested that the
low-level synthesis of nitric oxide induced by L. rhamnosus GG in macrophages and
colonic epithelial cells in vitro might be involved in the protective actions of the strain
(Korhonen et al. 2001).
Two mechanisms may explain the potential beneficial effects of prebiotics on colonic
inflammation: favourable changes in the intestinal microbiota and an increase in the
colonic short-chain fatty acid concentration. Short-chain fatty acids constitute the
primary energy source for the colonic epithelium, and are therefore important in
maintaining the integrity of the mucosa (for review, see Scheppach 1994). Ulcerative
colitis has been associated with lower butyrate oxidation by the colonic mucosa
(Hond et al. 1998), and though short-chain fatty acid enemas have not clearly been
shown to ameliorate the disease in humans (Scheppach et al. 1996, Breuer et al.
1997), butyrate has been effective in TNBS-induced colitis (Butzner et al. 1996).
To sum up, the possible mechanisms by which probiotics and prebiotics exert
beneficial effects on colitis include the production of antimicrobial substances, the
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stimulation of immunity and the normalization of increased mucosal barrier function.
The mechanisms behind prebiotics are thought to be the stimulation of the growth of
beneficial bacterial species and an increase in colonic short-chain fatty acid
concentration.
Experimental studies
There are not many studies on the attenuation of experimental colitis by probiotics
(Table V). The first study showed a highly protective effect of intracolonic
administration of L. reuteri R2LC on acetic acid-induced colitis, which was not simply
due to the presence of lactobacilli in general, since another strain, L. reuteri HLC,
was ineffective (Fabia et al. 1993b). The second provided evidence of the
antagonistic effect of the continuous intragastric infusion of L. reuteri R2LC on
another experimental model, methotrexate-induced enterocolitis, and introduced a
new colitis ameliorating strain L. plantarum DSM 9843, also called L. plantarum 299V
(Mao et al. 1996). Long-term L. reuteri via rectal delivery normalised the levels of
increased colonic mucosal-adherent and translocated bacteria and reduced the
severity of colitis in IL-10 gene-deficient mice (Madsen et al. 1999). Long-term oral
administration of a preparation containing bifidobacteria, lactobacilli and
Streptococcus salivarius ssp. thermophilus also improved histology, normalised
barrier integrity, and down-regulated the inflammatory response in this model
(Madsen et al. 2001). Histological injury in IL-10 gene-deficient mice has been
described as being reduced by oral therapy with L. salivarius ssp. salivarius UCC118
(O’Mahony et al. 2001) and with L. plantarum 299V (Schultz et al. 2002). Oral L.
plantarum 299, in contrast, has failed to improve TNBS-induced colitis (Kennedy et
al. 2000).
Studies on the effects of prebiotics on experimental colitis are very scarce. Oral
lactulose reduced the levels of increased colonic mucosal adherent and translocated
bacteria and attenuated the severity of colitis in IL-10 gene-deficient mice (Madsen et
al. 1999). This effect seemed to be due to the stimulation of the growth of lactobacilli.
Lactulose did not, however, attenuate macroscopic inflammation in severe colitis that
had been induced by TNBS, although it reduced systemic endotoxaemia in this
model (Gardiner et al. 1995). Inulin has been reported to attenuate DSS-induced
colitis (Videla et al. 2001). The effect of inulin is unlikely to be due to any direct
pharmacological action, since topical administration by enema has been ineffective
and yet faecal fluid from inulin-fed rats has shown an effect (Videla et al. 2001).
Table V. Probiotics used in experimental colitis.
*Methotrexate (i.p.) induces acute enterocolitis in rats (Mao et al. 1996).
Probiotics Model Protocol Results Reference
Lactobacillus reuteri R2LC (108 CFU day-1 intracolonically)
Lactobacillus reuteri HLC (108 CFU day-1 intracolonically)
Acetic acid Prevention Only Lactobacillus reuteri R2LC effective Fabia et al.
1993b
Lactobacillus reuteri R2LC (109 CFU day-1)
Lactobacillus plantarum DSM 9843 (also called Lactobacillus
plantarum 299V) (109 CFU day-1)
Methotrexate* Prevention Both strains effective Mao et al.
1996
Lactobacillus reuteri (107 CFU day-1 rectally) IL-10 gene-
deficient mouse
Prevention Effective Madsen et
al. 1999
Lactobacillus plantarum 299 (109 CFU day-1) TNBS Treatment Ineffective Kennedy et
al. 2000
Probiotic preparation VSL#3 (108 CFU day-1), containing
9 x 1010 CFU g-1 bifidobacteria (B. longum, B. infantis, B. breve),
8 x 1010 CFU g-1 lactobacilli (L. acidophilus, L. casei,
L. delbrueckii ssp. L. bulgaricus, L. plantarium),
20 x 1010 CFU g-1 Streptococcus salivarius ssp. thermophilus
IL-10 gene-
deficient mouse
Treatment Effective Madsen et
al. 2001
Lactobacillus salivarius ssp. salivarius UCC118 (109 CFU day-1) IL-10 gene-
deficient mouse
Treatment Slightly more effective than placebo O’Mahony
et al. 2001
 Lactobacillus plantarum 299V (1010 CFU day-1) IL-10 gene-
deficient mouse
Prevention/
treatment
Prevention: effective if given to germ-free
mice, ineffective if given to specific
pathogen-free mice;
Treatment: slightly more effective than
placebo
Schultz et
al. 2002
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Clinical trials
There are very few studies on the therapeutic efficacy of probiotics in human
inflammatory bowel diseases, and, to my knowledge, no clinical trials on prebiotics
exist. A randomised, double-blind, 12-week trial investigated the effects of non-
pathogenic Escherichia coli strain Nissle 1917 in comparison with mesalazine in
maintaining remission of ulcerative colitis (Kruis et al. 1997). No significant difference
between the treatment groups was observed, in spite of a tendency towards a slightly
higher clinical activity index in the Escherichia coli Nissle 1917 group. This finding
was confirmed in a randomised, double-blind, 12-month trial in which the Escherichia
coli Nissle 1917, with slow withdrawal of steroids, proved to be as effective as
mesalazine in preventing a relapse after an acute attack of ulcerative colitis
(Rembacken et al. 1999). This study, however, has been criticised because of its
high relapse rate (73% and 67% within 1 year in the mesalazine and Escherichia coli
groups respectively), which, in some studies, equals the relapse rate of the placebo
group (see Langman & Allan 1999).
2.3 ROLE OF EICOSANOIDS IN COLITIS
2.3.1 Leukotrienes
Synthesis and functions
Leukotrienes (LT) are synthesised from 20-carbon polyunsaturated fatty acids,
predominantly from arachidonic acid, through 5-lipoxygenase activity, which leads
first to the formation of unstable LTA4, which in turn is enzymatically converted either
to LTB4 or to LTC4 (Figures 1 and 2) (for reviews, see Lewis et al. 1990, Keppler
1992). LTC4 is further metabolised to LTD4, and subsequently to LTE4. LTC4, LTD4
and LTE4 are called cysteinyl leukotrienes. Like the most abundant precursor,
arachidonic acid, dihomo-γ-linolenic acid and eicosapentaenoic acid are also 5-
lipoxygenase substrates, and are converted to the three and five series of
leukotrienes, respectively, with less inflammatory activity compared to the four series
(for reviews, see Uotila & Vapaatalo 1984, James et al. 2000).
Leukotriene synthesis exhibits remarkable cellular specificity (for review, see
Lauritsen 1989). 5-lipoxygenase is found mainly in leukocytes, and neutrophils
primarily generate LTB4. LTC4 synthase is present in different inflammatory cells,
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Figure 1. Structures of arachidonic acid and key leukotrienes. AA, arachidonic acid.
Figure 2. 5-Lipoxygenase pathway to leukotriene generation (modified from Lewis et al. 1990,
Keppler 1992). AA, arachidonic acid.
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with eosinophils in the first place producing LTC4. Endothelial cells, platelets and
smooth muscle cells also express LTC4 synthase, and they can form LTC4 from LTA4
released from for example neutrophils in a process called the transcellular synthesis
of cysteinyl leukotrienes (for reviews, see Keppler 1992, Sala & Folco 2001). Indeed,
there is some evidence suggesting that LTA4, rather than LTB4, represents the main
metabolite released by neutrophils upon 5-lipoxygenase activation.
LTB4 acts via BLT-receptors that are found in leukocytes (for review, see Dahlén
1997). It is a very potent chemoattractive agent for leukocytes, primarily
polymorphonuclear leukocytes, stimulating adhesion, chemotactic movement,
aggregation, enzyme release and the generation of superoxide (for reviews, see
Samuelsson et al. 1987, Dahlén 1997). LTB4 also causes plasma exudation by
increasing microvascular permeability. Cysteinyl leukotrienes mediate their actions
through the cysteinyl leukotriene receptors cys-LT-1 and cys-LT-2, found in
pulmonary and gastrointestinal tissues (for review, see Dahlén 1997). Their primary
action is traditionally considered to be the stimulation of smooth muscle contraction,
especially in asthmatic lungs (for review, see Samuelsson et al. 1987). However,
they also cause the leakage of plasma by increasing microvascular permeability,
stimulate mucus secretion, and recruit eosinophils (for reviews, see Samuelsson et
al. 1987, Dahlén 1997). These actions are thought to be mediated through cys-LT-1
receptor stimulation, whereas the effects caused by cys-LT-2 receptor activation,
possibly including some vascular effects, are not clear (for review, see Dahlén 1997).
The potent proinflammatory activities of cysteinyl leukotrienes have only recently
attracted greater attention (for review, see Sala & Folco 2001). It has been
suggested that the activation of 5-lipoxygenase in neutrophils in close contact with
endothelial cells, for instance during adhesion, leads to the unexpected formation of
cysteinyl leukotrienes through transcellular synthesis, which in turn can give rise to
oedema formation during inflammation (for review, see Sala & Folco 2001).
Rationale for the use of drugs affecting leukotrienes
The formation of LTB4 increases in the intestinal mucosa in inflammatory bowel
diseases (for reviews, see Lauritsen 1989, Eberhart & Dubois 1995). LTB4 seems to
be the main chemoattractant in inflamed mucosa, and LTB4 levels correlate to
increased myeloperoxidase activity, a marker of neutrophil infiltration, and to disease
activity. During remission, LTB4 levels return to normal. Experimental colitis is also
consistently associated with high LTB4 levels (for review, see Eberhart & Dubois
1995). Drugs used for the treatment of inflammatory bowel diseases reduce
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leukotriene levels, although other mechanisms are also involved. These data,
therefore, support the direct involvement of LTB4 in the pathophysiology of
inflammatory bowel diseases. However, the increased formation of leukotrienes is
detected only in inflamed regions, whereas areas without inflammation retain their
normal leukotriene levels (for review, see Peskar 1989). This indicates that increased
production is not a primary defect but a secondary phenomenon in mucosal
inflammation.
Inflammatory bowel diseases are also associated with the increased mucosal
production of cysteinyl leukotrienes (Peskar et al. 1986, 1987, Wardle et al. 1993,
Casellas et al. 1994). In several models of experimental colitis, an increase in the
generation of cysteinyl leukotrienes has been demonstrated (Zipser et al. 1987a,
Eliakim et al. 1992, Karmeli et al. 1995, Rachmilewitz et al. 1995, Yuceyar et al.
1999, Oketani et al. 2001), and in one study it has been reported as correlating with
inflammatory cell infiltration (Zipser et al. 1987a). However, in the same models,
controversial observations also exist: the production of cysteinyl leukotrienes is not
always described as being enhanced in the inflamed colon (Zipser et al. 1987b,
Karmeli et al. 1995, Hammerbeck & Brown 1996), and even reduced levels have
been reported (Allgayer et al. 1989). Thus, cysteinyl leukotrienes have not been
convincingly shown to participate directly in the pathophysiology of inflammatory
bowel diseases.
Experimental studies
Different 5-lipoxygenase inhibitors have been studied in the treatment of
experimental colitis (Table VI). Of these, zileuton is the most often evaluated, and it
has been shown to reduce the severity of colitis in both the acute and the chronic
phase (Zingarelli et al. 1993, Bertrán et al. 1996, Zarif et al. 1996). There are two
reports on MK-866, a compound that inhibits 5-lipoxygenase activation through the
inhibition of enzyme translocation, accelerating the healing of experimental colitis
when the treatment is carried out during the early phase of the inflammatory reaction
(Wallace & Keenan 1990, Empey et al. 1992). There are individual studies on other
5-lipoxygenase inhibitors, which have shown either positive effects, such as
L651,392 (Wallace et al. 1989) and BAY y 1015 (Murthy et al. 1997), or no effect,
such as AA861, although this compound inhibited over 75% of LTB4 production
(LeDuc et al. 1993).
Table VI. 5-lipoxygenase inhibitors used in experimental colitis.
L651,392, 4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one; MK-886, 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid; AA861, 2-(12-
hydroxy-5,10-dodecadiynyl)-3,5,6-trimethyl-1,4-benzoquinone; BAY y 1015, R-(-)-2-cycloheptyl-N-methylsulfonyl-(4-(2-quinolinyl-methoxy)phenyl)-acetamide. *Inhibits the
activation of 5-lipoxygenase through inhibition of enzyme translocation. **Mitomycin-C (i.p.) induces colonic inflammation resembling human ulcerative colitis (not very popular
model). ***Inhibits arachidonic acid transfer to 5-lipoxygenase by inhibiting the 5-lipoxygenase−activating protein (FLAP).
Drugs Model Results Reference
L651,392 (10 mg kg-1 day-1 intracolonically) TNBS Early administration effective in acute as well as chronic colitis Wallace et al.
1989
MK-886* (3 or 10 mg kg-1 day-1 p.o.) TNBS Early administration of the larger dose effective in chronic colitis
but not in acute colitis
Late administration ineffective
Wallace &
Keenan 1990
MK-886* (10 mg kg-1 day-1 p.o.) Acetic acid Administration prior to colitis induction effective Empey et al.
1992
AA861 (100 mg kg-1 day-1 i.p.) Acetic acid Ineffective LeDuc et al.
1993
Zileuton (100 mg kg-1 day-1 p.o.) TNBS Effective in acute colitis Zingarelli et al.
1993
Zileuton (50 mg kg-1 day-1 intracolonically) TNBS Effective in chronic colitis, ineffective in acute colitis Bertrán et al.
1996
Zileuton (20 mg kg-1 day-1 p.o.) Mitomycin-C** Modest effect Zarif et al. 1996
BAY y 1015*** (16 or 48 mg kg-1 day-1 p.o.) DSS Both doses effective in acute as well as chronic colitis Murthy et al.
1997
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The effects of some cys-LT-1 receptor antagonists have been investigated in
experimental colitis models. Numerous different cys-LT-1 receptor antagonists exist,
whereas no specific cys-LT-2 receptor antagonists have yet been developed (for
review, see Dahlén 1997). One cys-LT-1 receptor antagonist, pranlukast (ONO-
1078), has been reported to ameliorate chronic TNBS-induced colitis (Nishikawa et
al. 1995). The cys-LT-1 receptor antagonists SKF-104,353 and SR 2640 have been
shown to prevent early colonic transit disturbances associated with TNBS-induced
colitis, in contrast to synthesis inhibitors and receptor antagonists of other
eicosanoids, indicating that cysteinyl leukotrienes mediate these alterations (Pons et
al. 1992). However, long-term motor alterations do not seem to be affected by cys-
LT-1 receptor antagonists (Morteau et al. 1993).
In conclusion, 5-lipoxygenase inhibition has proved effective in the treatment of
experimental colitis, especially in chronic TNBS models, whereas the effects of cys-
LT-1 receptor antagonists are still largely unknown.
Clinical trials
Some clinical trials have been conducted with inhibitors of leukotriene synthesis as
opposed to cys-LT-1 receptor antagonists. The 5-lipoxygenase inhibitor zileuton,
although shown to slightly improve mild to moderately active ulcerative colitis in one
small clinical trial (Laursen et al. 1994), has not proved effective as a maintenance
therapy in this disease (Hawkey et al. 1997). Similar results have been reported with
a 5-lipoxygenase−activating protein inhibitor, MK-591, which is ineffective in the
treatment of mild to moderately active ulcerative colitis, although it markedly inhibits
leukotriene synthesis (Roberts et al. 1997).
2.3.2 Prostanoids
Synthesis and functions
Prostanoids are formed from 20-carbon polyunsaturated fatty acids, predominantly
from arachidonic acid, mediated in the first place by prostaglandin G/H synthase
(PGG/H synthase), which exhibits two distinct catalytic activities, cyclooxygenase
and hydroperoxidase (for review, see Smith 1989). Cyclooxygenase catalyses the
formation of PGG2, whereas hydroperoxidase is required for the further formation of
PGH2, the essential precursor for the synthesis of all the prostanoids, PGD2, PGE2,
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Figure 3. Structures of arachidonic acid and key prostanoids. AA, arachidonic acid.
Figure 4. Biosynthetic pathway for prostanoid formation (modified from Smith 1989). AA,
arachidonic acid.
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PGF2α, PGI2 and TXA2 (Figures 3 and 4). In addition, dihomo-γ-linolenic acid can be
converted to the one series (e.g. PGE1) and eicosapentaenoic acid to the three
series (e.g. PGE3) of prostanoids, which are unlikely to be produced in sufficient
quantities to be important under normal circumstances (for review, see Morrow and
Roberts, II, 2001).
Two cyclooxygenase isoforms have been identified, referred to as COX-1 and COX-
2 (for reviews, see Dubois et al. 1998, Hinz & Brune 2002). COX-1 is the constitutive
isoform considered to be responsible for the maintenance of essential physiological
functions, and is found in almost all normal tissues. COX-2 is the inducible
isoenzyme, which apparently mediates many of the inflammatory effects of
cyclooxygenase, and is present at low to undetectable levels in normal tissue, but
upregulated at sites of inflammation. More recent studies have also suggested a
functional significance for COX-2.
Prostanoid synthesis occurs throughout the entire gastrointestinal tract (for reviews,
see Whittle & Vane 1987, Eberhart & Dubois 1995). Any given prostanoid-forming
cell tends to form only one prostanoid as its major product (for review, see Smith
1989). Whether cells within the mucosa contain the thromboxane synthetase enzyme
has yet to be determined, since it is possible that platelets in the mucosal
microcirculation may be responsible for TXA2 production (for review, see Whittle &
Vane 1987). The subepithelium produces most of the prostaglandins in the
gastrointestinal tract, although it is not entirely clear which cells are responsible (for
review, see Eberhart & Dubois 1995). They are most likely to be epithelial cells,
immune cells in the lamina propria, and subepithelial mesenchymal cells.
Prostaglandins produced in normal gastrointestinal tissue appear to be derived from
the COX-1 isoform localised in endothelial cells in submucosal blood vessels
(Kargman et al. 1996) and in crypt epithelial cells (Cohn et al. 1997). The expression
of COX-2 in normal gastrointestinal tissue, mainly in the colon, has been observed in
macrophages in Peyer’s patches or submucosal lymphoid aggregates, but it is only
an occasional finding, and COX-1 protein expression is approximately 2.5 times
greater than COX-2 isoform expression (Kargman et al. 1996).
Prostanoids act through specific receptors known as the PGD receptor (DP), the
PGE receptor (EP), the PGF receptor (FP), the PGI receptor (IP) and the TX receptor
(TP) (for review, see Narumiya et al. 1999). The cellular targets of prostaglandins in
the intestinal mucosa have not been fully explored, but according to one quite recent
report, EP receptor subtype 4 is expressed in 20% of the cells in the lamina propria,
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mainly in the mononuclear cells and the epithelial cells (Cosme et al. 2000).
Prostaglandins are important contributors to colonic motility and to water and
electrolyte secretion (for reviews, see Whittle & Vane 1987, Lauritsen 1989, Eberhart
& Dubois 1995). In addition, they stimulate mucus production, and, because of their
potent vasodilator actions, it is possible that they act as modulators of local blood
flow (for review, see Whittle & Vane 1987).
Rationale for the use of drugs affecting prostanoids
Prostanoid production increases in the colon in human IBD as well as in
experimental colitis models (for reviews, see Whittle & Vane 1987, Eberhart &
Dubois 1995). A positive correlation exists between the activity of the disease and
prostanoid synthesis (for review, see Eberhart & Dubois 1995). Levels return to their
normal values during remission of the disease and following pharmacological
treatment. Several prostaglandins, notably PGE2, have a pro-inflammatory capacity:
they enhance local vasodilatation and subsequent oedema formation, and may
account for the associated diarrhoea (for review, see Whittle & Vane 1987). High
local TXA2 levels could, in turn, contribute to intestinal damage as a consequence of
the compound’s vasoconstrictor properties.
However, as discussed above, prostaglandins appear to have physiological functions
in the gastrointestinal tract, and a growing body of evidence suggests that certain
prostaglandins are anti-inflammatory (for reviews, see Lauritsen 1989, Eberhart &
Dubois 1995). PGE2 suppresses various cellular immune functions in vitro
(Kabashima et al. 2002; for review, see Wallace & Tigley 1995). Prostaglandins also
accelerate cell production and differentiation after mucosal damage, stimulate mucus
production, and, because of their potent vasodilator action, might act as modulators
of local blood flow (for reviews, see Whittle & Vane 1987, Lauritsen 1989). These last
three are suggested as the mechanisms behind the possible cytoprotective
properties of prostaglandins (for review, see Lauritsen 1989).
Overall, evidence exists to support the potential beneficial effects of both decreasing
and increasing prostanoid levels in IBD, and both hypotheses have been abundantly
tested in the past.
Review of the literature
35
Experimental studies
The classic non-steroidal anti-inflammatory drugs (NSAID), i.e. non-selective
inhibitors of cyclooxygenase, have been investigated in the treatment and prevention
of experimental colitis in various models. Indomethacin has not only proved
ineffective in the treatment of formalin-immune complex–induced colitis and chronic
TNBS-induced colitis (Boughton-Smith et al. 1988, Schumert et al. 1988, Vilaseca et
al. 1990), but its administration has been associated with severe exacerbation of
acute colitis in acetic acid, TNBS and DSS models (Empey et al. 1992, Wallace et al.
1992, LeDuc et al. 1993, Kabashima et al. 2002). This effect is not restricted to
indomethacin, since naproxen and diclofenac, too, increase the severity of colitis in a
TNBS model (Wallace et al. 1992, Reuter et al. 1996). Acetylsalicylic acid is
ineffective in ameliorating chronic TNBS colitis (Boughton-Smith et al. 1988).
Experimental studies on non-selective inhibitors of cyclooxygenase show remarkable
consistency in their results, and only one study has found colitis ameliorating effects
with these agents (Mann & Demers 1983).
It has been suggested that selective inhibitors of COX-2 may spare physiological
gastrointestinal prostaglandin synthesis, and therefore lack the damaging effects
associated with NSAID, which, added to the inhibitory effects on the excess of
prostaglandin synthesis at sites of inflammation, would make them effective in the
treatment of IBD. There are no reports on the effects of selective inhibitors of COX-1
in IBD or in experimental colitis models. However, there are some studies on the
effects of moderately or highly selective COX-2 inhibitors in experimental colitis.
Treatment with the moderately selective COX-2 inhibitors nabumetone and etodolac
and with the highly selective inhibitor L745,337 resulted in exacerbation of TNBS-
induced colitis and increased mortality due to colonic perforations (Reuter et al.
1996). The highly selective COX-2 inhibitors NS-398, SC-58125 and PD-138387
have been described as being unable to ameliorate TNBS-induced colitis, but the
relevance of these results is questionable since the compounds used did not reduce
the synthesis of colonic PGE2 (Lesch et al. 1999). In addition, the moderately
selective inhibitors of COX-2, nimesulide and SC-236, have been reported to
ameliorate colitis in acetic acid- and iodoacetamide-induced colitis models (Karmeli
et al. 2000), and the nimesulide has been reported to reduce oedema formation and
neutrophil infiltration, but not macroscopic injury, in the acute phase of TNBS-
induced colitis (Kankuri et al. 2001). Thus, data concerning the effects of COX-2
inhibition in experimental colitis are scarce and fairly inconsistent. It is difficult to
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draw conclusions because of the different compounds used; perhaps some of the
discrepancies can be explained by the non-specific actions of some of these agents.
Pretreatment with exogenous prostaglandins has been shown to ameliorate intestinal
damage in experimental colitis models (Table VII). Pretreatments with PGE2 and its
analogue 16,16-dimethyl PGE2 protect rat colonic mucosa from acute damage
produced by exposure to ethanol (Wallace et al. 1985, Psaila et al. 1986), probably
by protecting the surface epithelial cells (Wallace et al. 1985). In an acetic acid
model, the protection by pretreatment with the PGE1 analogue misoprostol (Fedorak
et al. 1990, 1992, Yamada et al. 1991, 1992, Empey et al. 1992) is apparently not
related to the attenuation of the initial damage but to the acceleration of the rate of
mucosal restitution and repair (Yamada et al. 1992). The early phase of colitis
induced by acetic acid has been reported to benefit from PGE1, whereas later states
	
	et al. 1997). Results obtained in a TNBS model also
seem promising: early treatment with intraluminal 16,16-dimethyl PGE2 and the PGE1
analogue rioprostil are effective in acute as well as in chronic colitis, though oral
treatment is apparently ineffective (Allgayer et al. 1989, Wallace et al. 1989).
However, the PGE2 analogue enprostil has been reported to be effective only in early
TNBS colitis as opposed to the later phase (Onizuka et al. 2000). There are also
individual studies on the effects of exogenous prostaglandins in other models (Table
VII) (Schumert & Nast 1988, Sasaki et al. 2000). Finally, a selective EP4 receptor
agonist, AE1-734, ameliorates the severe form of DSS-induced colitis, whereas an
antagonist of this receptor, AE3-208, aggravates the mild colitis induced with DSS
(Kabashima et al. 2002).
There are only two experimental studies on drugs specifically affecting TXA2 in
colitis. Two selective TXA2 synthetase inhibitors, OKY 1581 and R 70416, have been
reported to reduce chronic colonic damage in a TNBS model (Vilaseca et al. 1990).
The TXA2 receptor antagonist ONO-NT-126 has also been described to markedly
reduce colonic damage in an acute TNBS model (Taniguchi et al. 1997).
Clinical trials
In the treatment of human IBD, non-selective NSAID are not only ineffective but
appear to reactivate quiescent disease, or even to induce colitis in subjects without
the disease (see Kaufman & Taubin 1987, Gibson et al. 1992). To my knowledge, no
clinical trials of the non-selective inhibitors of cyclooxygenase or COX-2 selective
inhibitors have been conducted on humans.
Table VII. Exogenous prostaglandins used in experimental colitis.
Drugs Model Results Reference
16,16-dimethyl PGE2 (0.05−20 µg kg-1 intrarectally) Ethanol Pretreatment effective Wallace et al.
1985
PGE2 (40 µg intracaecally) Ethanol Pretreatment effective Psaila et al.
1986
16,16-dimethyl PGE2 (6−200 µg kg-1 day-1 s.c.) Formalin/immune
complex
Doses 60-200 µg effective, single pretreatment dose ineffective Schumert &
Nast 1988
16,16-dimethyl PGE2 (20 mg kg-1 intracolonically) TNBS Early treatment effective in acute and chronic colitis Allgayer et al.
1989
PGE1 analogue rioprostil (20 µg kg-1
intracolonically, or 20 or 40µg kg-1 day-1 p.o.)
TNBS Single intracolonic pretreatment dose effective in chronic colitis,
daily oral treatment ineffective
Wallace et al.
1989
PGE1 analogue misoprostol (100 µg kg-1
intraluminally)
Acetic acid Pretreatment effective Fedorak et al.
1990
Misoprostol (50 µg intraluminally) Acetic acid Pretreatment effective Yamada et al.
1991
Misoprostol (100 µg kg-1 intraluminally) Acetic acid Pretreatment effective Empey et al.
1992
Misoprostol (100 µg kg-1 intraluminally) Acetic acid Pretreatment effective Fedorak et al.
1992
Misoprostol (50 µg intraluminally) Acetic acid Pretreatment effective Yamada et al.
1992
PGE1 (2 µg day-1 i.p.) Acetic acid Treatment effective only in early stage of colitis 7HU]LR÷OXet al.
1997
PGE2 analogue enprostil (200 µg day-1 intrarectally) TNBS Treatment effective only in early stage of colitis Onizuka et al.
2000
PGE2 (10 or 50 µg day-1 intrarectally) DSS Treatment effective in chronic colitis Sasaki et al.
2000
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Only one clinical trial has evaluated the potential beneficial effect of exogenous
prostaglandins in IBD. Oral 15(R),15-methyl-PGE2 failed to maintain ulcerative colitis
patients in remission (Goldin & Rachmilewitz 1983). The findings are, however,
complicated by the high incidence of diarrhoea among the patients who received this
prostaglandin analogue, possibly masking any beneficial effect.
Similarly, there is only one published clinical trial on the effects of drugs specifically
affecting TXA2 in IBD. A dual TXA2 synthase inhibitor and receptor antagonist,
ridogrel, failed to induce remission in moderately active Crohn’s disease (Carty et al.
2001).
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3 AIMS OF THE STUDY
The aim of the present study was to examine the effects of the treatment of
experimental colitis by affecting colonic microbiota and eicosanoids.
The specific aims were:
 To compare the effects of Lactobacillus rhamnosus GG and Lactobacillus
reuteri R2LC on acute colitis in rats (Study I).
 
 To investigate the effects of two different galacto-oligosaccharide mixtures on
the development of inflammation and on the growth of bifidobacteria in acute
colitis in rats (Study II).
 
 To study the influence of Lactobacillus rhamnosus GG on mucosal cell
kinetics and morphology in the intestine as one possible mechanism for colitis
attenuation (Study III).
 
 To evaluate the effects of the cys-LT-1 receptor antagonist montelukast on the
severity of the colonic damage and on the production of different eicosanoids
in acute colitis in rats (Study IV).
 
 To examine the effects of the cys-LT-1 receptor antagonist montelukast on the
severity of the injury and on the production of different eicosanoids in mild
colitis in rats (Study V).
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4 MATERIALS AND METHODS
4.1 MATERIALS
4.1.1 Experimental animals
Wistar and AGUS rats were used in the experiments (Table VIII). The Wistar rats
were purchased from the Laboratory Animal Centre, University of Helsinki, Finland,
and from Harlan, Horst, The Netherlands. An inbred germ-free AGUS strain of rats
was obtained from the Laboratory of Medical Microbial Ecology, Karolinska Institutet,
Stockholm, Sweden. The rats were housed either individually in cages (Studies I and
IV), two to three rats to a cage (Studies II and V), or in steel isolators (Study III). The
rats had free access to drinking fluid and standard rat chow, except during the 24-
hour fast preceding colitis induction in Study I and the food withdrawal 2.5 hours
before the vincristine injection in Study III.
The ethical aspects of these studies were approved by the Institutional Animal Care
and Use Committee, University of Helsinki, Finland, by the Provincial State Office of
Southern Finland, and by the Ethical Committee for Animal Research, Stockholm,
Sweden.
4.1.2 Probiotics
The probiotics L. rhamnosus GG and L. reuteri R2LC were used in the studies. L.
rhamnosus GG is the most extensively studied probiotic (for review, see Alvarez-
Olmos & Oberhelman 2001). It has been shown to be effective in the treatment of
diarrhoea due to acute gastroenteritis caused by rotavirus (Majamaa et al. 1995,
Rautanen et al. 1998) and some other pathogens (Raza et al. 1995, Pant et al. 1996,
Shornikova et al. 1997). L. reuteri R2LC has been shown to reduce the severity of
acetic acid-induced colitis and methotrexate-induced enterocolitis in rats (Fabia et al.
1993b, Mao et al. 1996).
In Study I, concentrates of L. rhamnosus GG (6 x 1010 ml-1) (Valio Ltd, R&D, Helsinki,
Finland) and L. reuteri R2LC (1.7 x 1010 ml-1) (gift from Göran Molin, University of
Lund, Sweden; grown by Valio) were used. The bacteria levels remained unchanged
in lactose-free cow’s milk kept at room temperature for at least 12 hours. In Study III,
L. rhamnosus GG was anaerobically grown in Man-Rogosa-Sharpe (MRS) medium
at 37°C for 24 hours, and aliquots were given to the rats.
Table VIII. Experimental animals.
Study Strain Status Number Gender Weight/ age Environment
I (L. rhamnosus GG,
   L. reuteri R2LC)
Wistar Conventional 40 Male 180−280 g 22 ± 1°C, humidity 40 ± 5%, light from
6 am to 6 pm
II (Galacto-oligosaccharides) Wistar Conventional 42 Male 170−300 g 22 ± 1°C, humidity 40 ± 5%, light from
6 am to 6 pm
III (Intestinal cell kinetics) AGUS Germ-free 21 Male 35 days 24 ± 2°C, humidity 55 ± 10%, light
from 6 am to 6 pm
IV (Montelukast, zileuton) Wistar Conventional 94 Male 200−260 g 22 ± 1°C, humidity 40 ± 5%, light from
6 am to 6 pm
V (Montelukast) Wistar Conventional 18 Male 150−190 g 22 ± 2°C, humidity 50 ± 10%, light
from 6 am to 8 pm
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4.1.3 Prebiotics
Two different galacto-oligosaccharide (GOS) mixtures were used in Study II: 1) a
concentrate prepared enzymatically from cow’s milk whey by Valio Ltd, Helsinki,
Finland, which contained 56% dry matter and 12% GOS composed of non-lactose
galactodisaccharides, and galactotrisaccharides; 2) a concentrate (Elix’or®) prepared
enzymatically from lactose by Borculo Whey Products, Borculo, Zwolle, The
Netherlands, containing 75% dry matter and 45% GOS mainly composed of non-
lactose galactodisaccharides, and galactotri- and galactotetrasaccharides. The
remainder of the concentrates were mainly lactose, glucose and galactose,
constituting a total of 37% and 30% in whey- and lactose-derived GOS concentrates
respectively. An example of the molecular structures of GOS is presented in Figure
5.
Figure 5. 3’-Galactosyl lactose [Gal-β(1,3)-Gal-β(1,4)-Glc], an example of the molecular
structures of GOS. The trisaccharide types of GOS are 1) Gal-β(1,y)-Gal-β(1,x)-Gal 2) Gal-β(1,y)-Gal-
β(1,x)-Glc 3) Gal-β(1,y)-Gal-(x,1)β-Gal and 4) Gal-β(1,y)-Glc-(x,1)β-Gal, where x and y represent the number of
the glycosidic bond carbon (2, 3, 4 or 6) on an adjacent monosaccharide. In the last two types x ≠ y.
Tetrasaccharides and larger saccharides can form branches. As a rule, GOS have not more than one Glc-group.
4.1.4 Leukotriene antagonist
A leukotriene antagonist, montelukast (Merck, Rahway, NJ, USA) (Figure 6),
licensed worldwide for the treatment of asthma, was used in Studies IV and V. It is a
potent, highly selective antagonist of cys-LT-1 receptors, with peak plasma
concentrations achieved approximately three hours after oral administration, a
bioavailability of 62%, and an elimination half-life of 5−6 hours (for review, see
Lipworth 1999). Montelukast was freshly prepared, and protected from light.
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Figure 6. The structure of montelukast.
4.1.5 Other materials
The following compounds were also used: acetic acid, dexamethasone (Oriola,
Espoo, Finland), dextran sulphate sodium (TdB Consultancy, Uppsala, Sweden),
halothane (ISC Chemicals, England), mebumal (Karolinska Hospital Pharmacy,
Stockholm, Sweden), sulphasalazine (Sigma, St. Louis, Mo, USA), trinitrobenzene
sulphonic acid (Fluka, Buchs, Switzerland), vincristine (Oncovin, Lilly S.A.,
Fegersheim, France), and zileuton (Abbott Laboratories, Chicago, Il, USA). The
compounds were freshly prepared, and protected from light.
4.2 COLITIS INDUCTION
4.2.1 Acetic acid (Study I)
The rats were given no food for 24 hours and then anaesthetised with halothane.
Colitis was induced using the technique described by Mascolo et al. 1995, with a
slight modification. A silicone balloon catheter fitted inside with small polyethylene
tubes was inserted intrarectally into the colon. The proximal colon was sealed off 8
cm from the anus by pushing air into the balloon, and a solution of 4% acetic acid (2
ml) was instilled into the colon distal to the balloon via the smaller tubes. The healthy
control rats were given saline.
4.2.2 Trinitrobenzene sulphonic acid (Studies II and IV)
Colitis was induced in halothane-anaesthetised rats using the technique described by
Morris et al. 1989. Briefly, a polypropylene catheter was inserted intracolonically to a
distance of 8 cm from the anus, and a 2,4,6-trinitrobenzene sulphonic acid (TNBS)
N
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O
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(60 mg kg-1) in 50% ethanol (1 ml kg-1) was instilled into the colon. In Study IV, the
healthy control rats were given saline.
4.2.3 Dextran sulphate sodium (Study V)
The animals received 4% dextran sulphate sodium (DSS) (molecular weight 45 000)
in their drinking water for nine days. The healthy control rats received water without
DSS.
4.3 TREATMENTS
The rats were randomly divided into groups (n = 5−10 in each group) to receive
different treatments:
Study I:   1)   A healthy control group receiving lactose-free milk
2) A colitis control group receiving lactose-free milk
3) A colitis group receiving L. rhamnosus GG (109−1010 CFU day-1) in
lactose-free milk
4) A colitis group receiving L. reuteri R2LC (109−1010 CFU day-1) in
lactose-free milk
5) A colitis group receiving sulphasalazine (100 mg kg-1 day-1) in
drinking water, and lactose-free milk
Lactose-free cow’s milk (40 ml day-1), with or without lactobacilli, was given daily
from the seventh day preceding colitis induction with acetic acid to the end of the
study. Sulphasalazine treatment was begun 12 hours before the colitis induction, and
was continued throughout the study. The 12-hour intake of the sulphasalazine-water
solution was measured in a pilot study, and the drug concentration was adjusted to
obtain the required daily dosage. Sulphasalazine, in the same dose as in the present
study, has previously been shown to attenuate colitis in this model (Fitzpatrick et al.
1990, Noa et al. 2000). The rats were killed 72 hours after the induction.
Study II: 1)  A healthy control group receiving the vehicle i.e. water
2) A colitis control group receiving the vehicle
3) A colitis group receiving whey-derived GOS (4 g kg-1 day-1, p.o.)
4) A colitis group receiving lactose-derived GOS (4 g kg-1 day-1, p.o.)
5) A colitis group receiving dexamethasone (2 mg kg-1 day-1, s.c.)
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Before the induction of colitis with TNBS, galacto-oligosaccharides (GOS) were
administered in drinking water, starting 10 days before the induction. After the
induction, GOS were given by gastric gavage. The 24-hour intake of the GOS-water
solution was measured in a pilot study, and the GOS concentration was adjusted to
obtain the required daily dosage. The first dexamethasone injection was given
immediately before the colitis induction and subsequently every 24 hours.
Dexamethasone, with half the dose used in the present study, has previously been
shown to attenuate colitis in this model (Appleyard & Wallace 1995). The rats were
killed 72 hours after the colitis induction.
Study III: 1)  A group of healthy germ-free rats
2) A group of healthy conventional rats
3) A group of healthy rats kept mono-associated with L. rhamnosus
GG for three days
4) A group of healthy rats kept mono-associated with L. rhamnosus
GG for 21 days
The mono-association was carried out by transferring ampoules containing L.
rhamnosus GG (10 ml, 109 CFU ml-1) into the isolator. Inside the isolator, the
ampoules were broken and 0.5−1 ml of the contents was given to the rats orally. The
remainder was spread on the fur and the bedding material. The rats were killed three
or 21 days after the beginning of the study.
Study IV:   Groups sacrificed 24 hours after induction:
1) A healthy control group receiving the vehicle i.e. 1%
methylcellulose
2) A healthy group receiving montelukast (10 mg kg-1 day-1)
3) A healthy group receiving zileuton (100 mg kg-1 day-1)
4) A colitis control group receiving the vehicle
5) A colitis group receiving montelukast (5 mg kg-1 day-1)
6) A colitis group receiving montelukast (10 mg kg-1 day-1)
7) A colitis group receiving montelukast (20 mg kg-1 day-1)
8) A colitis group receiving zileuton (50 mg kg-1 day-1)
9) A colitis group receiving zileuton (100 mg kg-1 day-1)
Groups sacrificed 72 hours after induction:
   10)  A colitis control group receiving the vehicle
   11) A colitis group receiving montelukast (10 mg kg-1 day-1)
      12) A colitis group receiving zileuton (100 mg kg-1 day-1)
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The drugs were suspended in 1% methylcellulose and administered intracolonically
(1 ml kg-1) to a distance of 8 cm from the anus directly at the site of inflammation
while the rats were under halothane anaesthesia. Treatment began the night
preceding the induction of colitis with TNBS and was given twice a day throughout
the study. The same doses of zileuton as in the present study have previously been
shown to reduce the severity of colitis in this model (Zingarelli et al. 1993, Bertrán et
al. 1996).
Study V:   1)   A healthy control group receiving the vehicle i.e. water
2) A colitis control group receiving the vehicle
3) A colitis group receiving montelukast (10 mg kg-1 day-1, p.o.)
Montelukast and the vehicle were administered by gastric gavage. The treatment
began concurrently with DSS administration and was given daily throughout the
study i.e. for nine days.
4.4 ASSESSMENT OF INFLAMMATION
4.4.1 Gross assessment (Studies I, II, IV and V)
The animals were weighed every day during the study. In addition, in Study V, the
stool consistency (normal, loose stools, diarrhoea), gross bleeding and the presence
of occult blood in the stools were evaluated on the last four days of the study. The
rats were killed at various timepoints by decapitation preceded by an overdose of
CO2. The descending colon was cut at pubic symphysis and either at 7 cm proximally
(Studies I, II and IV) or at the caecum (Study V). The colon was incised along its
mesenteric border and gently washed. Colon-to-body weight was calculated as an
index of tissue oedema.
In Studies I, II and IV, the colon was then placed flat, mucosal surface upwards, and
photographed for macroscopic evaluation (colonic damage score) as described by
Kankuri et al. 1999. The severity of inflammation was evaluated by five experienced
observers unaware of the treatments, using a visual analogue scale (100 mm;
minimum injury 0, maximum injury 100).
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4.4.2 Histology (Studies I, IV and V)
The whole-wall specimens of the colon for histological examination were taken either
from the section adjacent to the macroscopically most intensively affected area
(Study IV) or from a predetermined location in the distal colon (Studies I and V). The
specimens were suspended in formaldehyde, embedded in paraffin, cut, and stained
with hematoxylin and eosin. Histological assessment by light microscopy was carried
out by two observers unaware of the treatments. In addition, in Studies I and IV, the
degree of inflammation was graded using the criteria described by González et al.
1999, and the score represented the sum of six individual variables graded 0−3
depending upon the severity of the changes (0 = no change; 1 = mild; 2 = moderate;
3 = severe). The variables evaluated were: erosion, ulceration, necrosis,
haemorrhage, oedema and inflammatory cell infiltration.
4.4.3 Myeloperoxidase activity (Studies I, II, IV and V)
An assay of colonic myeloperoxidase (MPO) activity was used to quantify neutrophil
infiltration, and was determined by the method described by Pfeiffer & Qiu 1995. In
Studies I, IV and V, MPO activity was measured from the whole-wall specimens,
whereas in Study II, only the mucosal layer was used. One unit of myeloperoxidase
activity was defined as that which degraded 1 µmol of hydrogen peroxide in 1 min,
and was expressed as [unit g-1] of tissue.
4.4.4 Eicosanoid production (Studies IV and V)
Immediately after cutting, the colon was transferred to Krebs buffer (pH 7.5), which
was gently oxygenated with 95% O2 − 5% CO2. A 5-mm segment was cut either from
the macroscopically most intensively affected region (Study IV) or from a pre-
determined location in the distal colon (Study V). The sample was placed in a pre-
weighed tube containing Krebs buffer, and weighed. It was then first pre-incubated in
Krebs buffer (pre-oxygenated with 95% O2 − 5% CO2) for 15 min at 37°C to minimise
the effect of sample handling, after which the buffer was discarded and the tissue
was incubated in pre-oxygenated Krebs buffer for another 15 min at 37°C. At the end
of the incubation period the media were collected, centrifuged and stored at -80°C. In
Study V, after the 15-min incubation, the sample was cut into 1-mm pieces and
incubated in 3 ml of RPMI 1640 medium for a further 24 hours at 37°C. After
incubation the media were collected, centrifuged and stored at -80°C. The PGE2 and
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bicyclic-PGE2 radioimmunoassay kits came from the Institute of Isotopes (Budapest,
Hungary). Bicyclic-PGE2 (13,14-dihydro-15-keto-11β,16ε-cyclo-PGE2) is a stable
end-product of 13,14-dihydro-15-keto-PGE2, the main PGE2 metabolite found in the
circulation. The LTB4 radioimmunoassay kit (Study IV) and the enzymeimmunoassay
kit (Study V) were purchased from Amersham (Buckinghamshire, England, UK). The
TXB2 radioimmunoassay was performed as described by Saareks et al. 1999. In
Study IV, leukotrienes C4/D4/E4 were determined both by radioimmunoassay (Alanko
et al. 1992), and by the enzymeimmunoassay from Amersham. In Study V, they were
determined only by radioimmunoassay.
4.4.5 Western blot of iNOS, COX-1 and COX-2 (Studies I, IV and V)
iNOS (inducible nitric oxide synthase) is an enzyme induced in inflammatory
reactions, and high levels of its product, nitric oxide, are believed to cause intestinal
injury (for reviews, see Perner & Rask-Madsen 1999, Kubes 2000).
The whole-wall colon samples were homogenized in boiling buffer and centrifuged.
Equal amounts of protein from each sample were separated in a sodium dodecyl
sulphate polyacrylamide gel and transferred to a nitrocellulose membrane. The
primary antibody used was either rabbit polyclonal anti-iNOS IgG (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), goat polyclonal anti-COX-1 IgG (Santa Cruz
Biotechnology), or goat polyclonal anti-COX-2 IgG (Santa Cruz Biotechnology). The
horseradish peroxidase-coupled secondary antibody was either anti-rabbit IgG
(Santa Cruz Biotechnology) (iNOS) or anti-goat IgG (Zymed Laboratories, San
Francisco, CA, USA) (COX-1, COX-2). Bound antibodies were detected using an
enhanced chemiluminescence reaction. The optical density of each band was
quantified using specific computer programmes (GeneSnap and GeneTools,
Synoptics, Cambridge, UK).
4.4.6 Immunohistochemistry for ED1 antigen and COX-2 (Study V)
Colonic tissue was fixed as described above, under the heading of histology. The
deparaffinized sections were first incubated in the blocking serum, followed by
incubation with the primary antibody, either mouse monoclonal ED1 IgG (Serotec,
Oxford, UK) or rabbit polyclonal anti-COX-2 IgG (Cayman Chemical, Ann Arbor, MI,
USA). ED1 recognises a lysosomal membrane protein (ED1 antigen) expressed by
the majority of tissue macrophages. After the primary antibody, the sections were
incubated in a biotinylated secondary antibody, either anti-mouse IgG (Vector
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Laboratories, Burlingame, CA, USA) (ED1) or anti-rabbit IgG (Vector Laboratories)
(COX-2). The sections were then incubated with peroxidase-labelled biotin-
avidin−complex using a commercial Elite ABC kit (Vector Laboratories). The colour
was developed by incubation in a 3-amino-9-ethyl carbazole solution containing
hydrogen peroxide. Finally, sections were counterstained with Mayer’s hemalum and
mounted in an aqueous mounting medium. Sections incubated with either normal
mouse IgG (ED1) or normal rabbit IgG (COX-2) served as negative controls. The
specimens were examined by Leica DMR microscope (Leica Microsystems, Wetzlar,
Germany) and photographed using specific computer programmes.
4.5 ASSESSMENT OF INTESTINAL CELL KINETICS (STUDY III)
Crypts are the suppliers of new epithelial cells in the intestine, with the cells
constantly migrating upwards along the epithelium out of the crypts and, in the small
intestine, to the base of the villus and then following the length of the villus until they
exfoliate from the tip of the villus. By assessing cell kinetics, i.e. the rate of mitoses,
the number of epithelial cells in the villi and in the crypts, the depth of the crypts and
the height of the villi, the production of epithelial cells can be evaluated. Increased
cell production contributes to enhanced mucosal regeneration.
4.5.1 Preparation of specimens
The cells were blocked in the metaphase by a vincristine injection 2.5 hours following
food withdrawal. Four hours after the vincristine, the rats were laparotomised in
mebumal anaesthesia. Specimens were taken from the duodenum, the jejunum at
15 cm and 40 cm distal to the pyloric region, the ileum at 5 cm proximal to the ileo-
caecal junction, the caecum at its base, and from the colon at 2−3, 5−6 and 8−9 cm
distal to the caecum. The specimens were cut open along their longitudinal axis and
fixed in Carnoy’s solution and ethanol, then embedded in paraffin and stained with
hematoxylin and eosin. Assessment by light microscopy was carried out in a blinded
fashion.
4.5.2 Mitotic index
The total number of mitotic cells and cell nuclei were counted in the left-hand column
of 30 well-oriented crypts in all the sections. The mitotic index (MI) is the percentage
of cells in the metaphase or in the mitotic phase before the metaphase (Wright et al.
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1972), and is calculated by the formula MI = Nm/Nt x 100, where Nm is the number
of mitotic cells and Nt is the total number of cells in the left-hand column of the crypt.
4.5.3 Number of epithelial cells
The number of cells in the left-hand column of 30 well-oriented crypts in the small
intestine and in the colon, and in the left-hand column of the villi in the small
intestine, was counted.
4.5.4 Depth of crypts and height of villi
In the small intestine the depth of 20 well-oriented crypts was measured from the
base of the crypt to the crypt-villus junction, and the height of 20 villi was measured
from the crypt-villus junction to the tip of the villus by using a micrometer in the ocular
eye-piece (magnification x 100). In the same way, the depth of the colonic crypts was
measured from the base of the crypt to the margin of the colonic mucosa.
4.6 MICROBIOLOGICAL MEASUREMENTS
4.6.1 L. rhamnosus GG in the faeces (Studies I and III)
In Study I, faecal samples were taken from the incised colon, serial dilutions of faecal
samples were cultivated on MRS-vancomycin agar plates at 37°C for 3 days under
aerobic conditions, and typical L. rhamnosus GG colonies were counted. L.
rhamnosus GG colonies were further tested on lactose-indicator agar for their ability
to ferment lactose. L. rhamnosus GG does not ferment lactose and forms white
colonies on this agar. All lactose-negative colonies were identified by the L.
rhamnosus species-specific polymerase chain reaction (Alander et al. 1999).
Identification of the strain GG was based on the strain-specific profile obtained by
NotI and SfiI restriction enzymes in pulsed-field gel electrophoresis (Tynkkynen et al.
1999).
In Study III, faecal samples were taken at laparotomy, and bacterial establishment
was verified by incubating them anaerobically in MRS broth at 37°C. The samples
were inspected for growth every day for 3 days.
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4.6.2 Bifidobacteria in the faeces (Study II)
Faecal samples were taken from the colitis control group and the groups
administered with different GOS at the beginning of the study, before the induction of
colitis and before the animals were sacrificed. Serial dilutions of faecal samples were
cultivated on MRS medium containing cysteine-HCl, on Raffinose-Bifidobacterium
medium (Hartemink et al. 1996) and on Beerens medium (Beerens 1991), at 37°C
for 4−5 days under anaerobic conditions. The total number of colonies on MRS
medium, and the typical Bifidobacterium colonies on MRS medium, Raffinose-
Bifidobacterium medium and Beerens medium were counted. Bifidobacteria were
identified on the basis of their typical morphology, and typical colonies from each
faecal specimen were investigated further for their microscopic morphology and
aerotolerance. Bifidobacteria do not grow in aerobic conditions.
4.7 STATISTICAL ANALYSIS
In Study I, data are expressed as medians (ranges) or as individual values with
medians, in Study III as means ± SD, and in Studies II, IV and V as means ± SEM. In
Studies I, II and V, statistical analyses were carried out using the Kruskal-Wallis test,
and when this indicated a significant effect, the Mann-Whitney U-test was used. In
Study IV, only the Mann-Whitney U-test was used. The one-way analysis of variance
(ANOVA) was used in Study III. P values of < 0.05 were considered statistically
significant.
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5 RESULTS
The summary of the results is shown in Table XI (page 57). The individual results of
Studies I−V are presented in the following chapters.
5.1 EFFECTS OF MODULATING MICROBIOTA ON EXPERIMENTAL
COLITIS
5.1.1 Effects of L. rhamnosus GG and L. reuteri R2LC (Study I)
L. rhamnosus GG was detected in the faeces of every animal fed this strain (7.23 ±
0.42 log10 CFU g-1)
The acetic acid treatment induced severe macroscopic inflammation in the colon 72
hours after intraluminal application, as assessed from the colonic damage score. The
histological assessment of colitis showed erosion, ulceration, necrosis,
haemorrhage, oedema and inflammatory cell infiltration. L. rhamnosus GG and L.
reuteri R2LC did not affect the severity of gross or histological inflammation.
Colonic inflammation was also associated with colonic oedema, neutrophil
accumulation and weight loss apparently due to reduced food intake. L. rhamnosus
GG and L reuteri R2LC did not reduce these alterations, although the mean of
myeloperoxidase activity in the group administered with L. reuteri R2LC (620 ± 110 U
g-1) was only 50% that of the colitis control group (1210 ± 370 U g-1).
iNOS and COX-2 protein expressions increased in the colon in all the colitis control
samples, whereas in the healthy samples no expression was detected. L. rhamnosus
GG and L. reuteri R2LC did not influence iNOS or COX-2 expression.
Sulphasalazine did not show any effect in treating acetic acid induced colitis, in fact,
it increased oedema formation and body weight loss.
To sum up, the acetic acid model of colitis in our laboratory showed resistance to L.
rhamnosus GG and L. reuteri R2LC, as well as to sulphasalazine.
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5.1.2 Effects of galacto-oligosaccharides (Study II)
Both whey-derived and lactose-derived GOS stimulated the growth of bifidobacteria
in TNBS colitis (Table IX).
Table IX. Increase in the growth of faecal bifidobacteria caused by GOS as compared
to the control group.
↔, no effect; *significantly different from the control group.
GOS also stimulated the growth of total bacteria on MRS medium, showing
maximally doubled levels before induction. After the induction of colitis, the total
bacteria growing on MRS medium tended to decrease in the colitis control group,
whereas GOS administration seemed to antagonise this effect. Therefore, although
GOS did not seem to be entirely specific to bifidobacteria, their effect on the total
bacteria growing on MRS medium was smaller than their effect on bifidobacteria.
TNBS induced severe macroscopic damage and inflammation in the colon, oedema
formation, neutrophil infiltration and modest weight loss 72 hours after TNBS
application. The GOS were ineffective in reducing these changes.
Dexamethasone treatment almost completely antagonised oedema formation, but it
was not effective in attenuating colitis, and the rats administered with
dexamethasone lost 10% more weight than the rats in the colitis control group.
To sum up, in the acute TNBS-induced model used, GOS were able to stimulate
bifidobacteria growth but not to ameliorate colitis.
MRS medium Raffinose-Bifidobacterium medium
Before induction After induction Before induction After induction
Whey-derived GOS 200% 300%* 400% 300%
Lactose-derived GOS 100% ↔ 1800%* 500%*
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5.1.3 Effects of L. rhamnosus GG on intestinal cell kinetics (Study
III)
In all the rats administered with L. rhamnosus GG, this strain was detected in the
luminal content at a concentration of at least 107 CFU g-1.
The effects of mono-association with L. rhamnosus GG for 3 and 21 days on
mucosal cell kinetics and morphology in the large intestine are summarised in Table
X. After 21 days of mono-association with L. rhamnosus GG, mitotic activity
increased in the crypts of the caecum but not of the colon, compared to the
conventional and the germ-free rats, whereas 3-day mono-association had no effect
on the rate of mitoses in the large intestine. Mono-association increased the mitotic
activity of the crypts of the small intestine, the changes being most notable in the
jejunum.
Table X. Summary of the effects of L. rhamnosus GG on crypt cell kinetics and
morphology in the large intestine.
↑, increased; ↓, decreased; ↔, no effect.
The number of caecal and colonic crypt cells also increased after mono-association,
after both 3 days and 21 days. In the small intestine, in contrast, an increase in the
number of cells in the crypts was seen only after 21 days of mono-association, and
the effect was less pronounced than in the large intestine.
3 day mono-association 21 day mono-association
vs. germ-free rats vs. conventional
rats
vs. germ-free rats vs. conventional
rats
Mitotic index ↔ ↔ ↑
(caecum, 25%)
↑
(caecum, 25%)
Number of crypt cells ↑
(caecum, 40%,
colon 20%)
↑
(caecum, 15%)
↑
(caecum, 50%,
colon 20%)
↑
(caecum, 30%)
Crypt depth ↓
(caecum, 10%)
↓
(caecum, 20%,
colon 20%)
↑
(caecum, 10%,
middle colon 20%)
↓
(colon 20%)
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The mono-association of L. rhamnosus GG generally led to shorter crypts throughout
the length of the intestine. The only exception was the increased crypt depth in the
caecum and in the middle segment of the colon.
In addition, at both timepoints, the number of villus cells increased in all parts of the
small intestine compared to the germ-free (25−35%) and the conventional rats
(15−50%). The villi in the small intestine of rats mono-associated with L. rhamnosus
GG were also on the whole approximately 20% taller than the villi of the conventional
rats.
To sum up, L. rhamnosus GG increased the production of epithelial cells in both the
small and the large intestine in rats mono-associated with this strain.
5.2 EFFECTS OF MODULATING EICOSANOIDS ON EXPERIMENTAL
COLITIS
5.2.1 Effects of cys-LT-1 receptor blockade on severe colitis (Study
IV)
TNBS treatment induced severe macroscopic and microscopic inflammation in the
colon both 24 hours and 72 hours after colitis induction. Histological assessment
showed necrosis, haemorrhage, oedema, inflammatory cell infiltration, erosion and
ulceration. Colonic inflammation was also associated with oedema, neutrophil
accumulation and marked weight loss. The cys-LT-1 receptor antagonist montelukast
did not reduce the inflammation, as assessed by any of the parameters mentioned
above, although 72 hours after the colitis induction it reduced the mean value for
myeloperoxidase activity by 50% (P = 0.27).
The in vitro colonic production of PGE2, LTB4 and TXB2 increased after TNBS
application, both 24 hours and 72 hours after the induction, whereas the production
of bicyclic-PGE2 decreased. No cysteinyl leukotriene production was detected. Both
the low-dose montelukast group and the high-dose group had a 30−40% increase in
the production of PGE2 or its metabolite. Montelukast did not modify LTB4 or TXB2
production.
COX-2 and iNOS protein expression increased in the colon after the colitis induction.
Montelukast had no statistically significant effect on either of these proteins, but there
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was an almost 40% decrease in COX-2 expression 72 hours after the induction in the
group administered with montelukast (P = 0.15).
Zileuton did not ameliorate the inflammatory reaction in spite of the fact that it
reduced LTB4 production by 40% 72 hours after the induction.
To sum up, montelukast administration increased the in vitro production of
prostaglandins in acute severe colitis induced by TNBS. However, it was, like
zileuton, ineffective in attenuating the colonic damage.
5.2.2 Effects of cys-LT-1 receptor blockade on mild colitis (Study V)
DSS induced bloody diarrhoea from day 6 onwards, but did not reduce weight gain.
Macroscopically, the colons of the colitis control group did not differ from those of the
healthy control group, and colon wet weight was similar in all the groups, indicating
that colitis was not associated with significant oedema. The histological changes
were small except for the increased inflammatory cell infiltration. Montelukast
increased weight gain and reduced occult blood in the faeces/ gross bleeding by
30% at the end of the experiment without affecting diarrhoea.
The in vitro colonic production of LTB4 within 15 minutes increased in the colitis
control group. The levels of the cyclooxygenase products PGE2, bicyclic-PGE2 and
TXB2 remained unchanged in both the 15-minute and the 24-hour incubations.
Cysteinyl leukotrienes were not measurable in the 15-minute incubation but in the
24-hour incubation high levels of cysteinyl leukotrienes were produced, though there
were no differences between the healthy and the colitis animals. The ratio of LTB4/
PGE2 production during the 15-minute incubation period was 2.5 times higher in the
colitis control group than in the healthy control group, but the difference was not
statistically significant. The same trend was seen in the ratio of LTB4/ bicyclic-PGE2,
which increased 2.5-fold in the colitis control group, too. Montelukast administration
did not significantly influence eicosanoid production, but it reduced the ratio of LTB4/
PGE2 production within the 15 minutes by 60% (Kruskal-Wallis P = 0.108; Mann-
Whitney P = 0.076).
Both iNOS protein expression and protein recognised by ED1 increased in the
inflamed colon, whereas COX-1 was expressed in every specimen at approximately
the same level. COX-2 was not detected by Western blot in either the inflamed or the
healthy colons, and COX-2 expression detected by immunohistochemistry in the
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mucosal layer was the same in both the healthy and the colitis control groups.
Montelukast had no effect on the expression of any of these proteins.
To sum up, montelukast reduced occult blood in the faeces/ gross bleeding,
maintained normal body weight gain and tended to decrease the ratio of LTB4/ PGE2
production in the colon in vitro in mild colitis induced by DSS.
Table XI. Summary of the effects of L. rhamnosus GG, L. reuteri R2LC, galacto-
oligosaccharides and montelukast on different forms of experimental colitis.
LGG, L. rhamnosus GG; LR2LC, L. reuteri R2LC; ↑, increased; ↓, decreased; ↔, no effect; (), tendency. *First
arrow indicates the effect 24 hours after colitis induction, the second, 72 hours after induction.
Acetic acid TNBS TNBS DSS
LGG LR2LC GOS(whey) GOS(lactose) Monte Monte
Weight gain ↔ ↔ ↔ ↔ ↔ ↑
Loose faeces/ diarrhoea ↔
Occult blood/ bleeding ↓
Colonic damage score ↔ ↔ ↔ ↔ ↔
Colonic oedema ↔ ↔ ↔ ↔ ↔
Histological damage ↔ ↔ ↔
Myeloperoxidase activity ↔ (↓) ↔ ↔ ↔, (↓)*
COX-2 ↔ ↔ ↔, (↓)* ↔
iNOS ↔ ↔ ↔ ↔
ED1 Antigen ↔
PGE2 (or its metabolite) ↑, ↔* ↔
TXB2 ↔ ↔
LTB4 ↔ ↔
LTB4/ PGE2 (↓)
LTB4/ bicyclic-PGE2 ↔
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6 DISCUSSION
6.1 METHODOLOGY
6.1.1 Colitis models
The colitis models used in the present study (acetic acid, TNBS and DSS models)
are widely used to induce colitis in experimental animals (for review, see Dieleman et
al. 1997). Acetic acid and TNBS-induced models are much more severe than the
DSS model, with the first two characterized by weight loss and severe macroscopic
and histological damage in the colon, and the TNBS model by transmural injury.
Macroscopic injury in both acetic acid and TNBS models is found in different areas in
different animals, with a clear boundary between the macroscopically healthy and the
diseased tissue, which means that the sampling section must be clearly determined
beforehand. DSS induces a much less severe colitis, without clear macroscopic
damage.
The relevance of the choice of acetic acid and TNBS models for studying the effects
of lactobacilli and GOS may be questioned because of the serious nature of these
models. However, the acetic acid application has been shown to result in reduced
colonic mucosa-associated lactobacilli and reduced total lactic acid bacteria (Fabia et
al. 1993a), and certain lactobacilli have been shown to have a highly protective effect
in this model (Fabia et al. 1993b). In an acute TNBS model, on the other hand, faecal
lactobacilli are reported to be completely absent, in contrast to the predominance of
lactobacilli among the aerobic isolates in healthy rats (Videla et al. 1994). TNBS-
induced colitis is also associated with other alterations in the colonic microbiota
(Gardiner et al. 1993, García-Lafuente et al. 1997), and can be attenuated by
antibiotic treatment (Videla et al. 1994). A DSS model is not suitable for the
investigation of the effects of compounds affecting the colonic microbiota, since it is a
polysaccharide and as such can itself act as a substrate for intestinal microbes
(Galanos et al. 1969).
It is worth noting that the severity of the models used is dependent not only on the
dosage and the time of exposure to the irritant used, on the nature of the polymer (in
the case of DSS), as well as on the animal strains used, but also on the environment
of the laboratory in which the study takes place and in particular on the microbial
status of the conventional animals. Therefore, the severity of a certain model in one
laboratory cannot be deduced directly from observations by other observers in other
Discussion
59
laboratories, but has to be judged within the environment where the study is to be
conducted.
The acetic acid and TNBS-induced colitis models in the present study appear severe
because the reference drugs were ineffective. Sulphasalazine, which had no
beneficial effect in our study, has been previously shown to ameliorate acetic acid-
induced colitis in the same dose as we used (Fitzpatrick et al. 1990, Noa et al. 2000).
Similarly, dexamethasone was ineffective in attenuating TNBS-induced colitis in our
study. Others, too, have come across difficulties in demonstrating the colitis-
ameliorating effects of dexamethasone in this model (Fries et al. 1998), although
studies reporting positive effects also exist (Appleyard & Wallace 1995, Bobin-
Dubigeon et al. 2001). Zileuton, too, was unable to reduce the severity of TNBS-
induced colitis in our study, in contrast to previous reports where zileuton was seen
to reduce the intensity of inflammatory reaction in this model (Zingarelli et al. 1993,
Bertrán et al. 1996).
The severity of the models used might be the underlying reason for the lack of effect
of some agents with marginal therapeutic effects. Therefore, no final conclusion
about the possible beneficial effects of probiotics, prebiotics and a leukotriene
antagonist on experimental colitis can be drawn from the present studies.
6.1.2 Assessment of inflammation
The golden standards for the assessment of the inflammatory damage in the colon
are macroscopic and histological evaluation. The macroscopic damage in the colon
was evaluated by five observers unaware of the treatments, using a visual analogue
scale (Kankuri et al. 1999). The limitation of this method is that it only gives a gross
estimation of the severity of the damage, and subtle changes, as well as the nature
of the changes, are missed. The reliability of the method was estimated by
comparing the results with two other visual estimation methods, which gave similar
results.
Histological evaluation was carried out by two observers unaware of the treatments.
The degree of inflammation was graded using the sum of six individual parameters
(erosion, ulceration, necrosis, haemorrhage, oedema and inflammatory cell
infiltration) graded 0−3 depending on the severity of the changes (González et al.
1999). This method is more sensitive to subtle changes, and it is also possible to
describe the nature of the changes. When variability in the location of the injury in the
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colon is taken into account, it is better for histology to be conducted from several
parts of the colon to avoid the possibility of chance. However, in this study histology
was only carried out from one segment of the colon, and therefore the reliability of
the results obtained may be questioned.
Eicosanoid production in the colon was assessed after 15 minutes and after 24 hours
of in vitro tissue incubation. The determination of tissue levels of eicosanoids is not
only methodologically complex but susceptible to bias, since the handling of the
specimen affects eicosanoid synthesis (for review, see Bukhave 1992). In the
present study, the ability of the colon to produce eicosanoids in the incubation
medium was measured, so the eicosanoid measurement needed no extraction
procedures. Special attention was paid to the standardization of the tissue handling,
and a pre-incubation was included to minimise the effect of sample handling. In vitro
incubation was begun immediately after the cutting of the tissue. The tissue had to
be weighed before incubation, and because of the sensitivity of eicosanoid
production to exogenous stimulus, the specimen could not be manually dried, and
therefore the weight of the sample could not be exact. This may have led to some
inaccuracies in the results. Nevertheless, the deviation within groups was
reasonable.
6.2 EFFECTS OF MODULATING MICROBIOTA ON EXPERIMENTAL
COLITIS
L. rhamnosus GG and L reuteri R2LC did not affect the severity of acute acetic acid-
induced colitis. GOS, although stimulating bifidobacteria growth, were also unable to
attenuate acute colitis induced by TNBS. The hypothesised mechanisms of
lactobacilli and bifidobacteria in the attenuation of colitis, i.e. the production of
antimicrobial products, the decrease in intestinal permeability, the promotion of gut
IgA response, and also, in the case of GOS, the increase in the colonic short chain
fatty acid concentration, mainly concern the inhibition of potentially pathogenic
bacteria from interacting with colonic mucosa. In acute inflammation and necrosis
induced by acetic acid or TNBS, the interaction between the luminal bacteria and the
mucosa is apparently not the primary or even the secondary pathogenic alteration.
Hypothetically, this interaction might be more important in the phase during which the
acute inflammation begins to heal. Therefore these mechanisms are probably less
effective in an acute model, but may have better potential to affect chronic, and less
severe, colitis. Some support for this conclusion is found in a study in which certain
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antimicrobial drugs were seen to attenuate damage in the phase of TNBS-induced
colitis when the inflammation begins to heal (Videla et al. 1994). Regrettably, there
are no reports on the effects of antimicrobial drugs in the acetic acid model or in the
most acute phase of inflammation in the TNBS model. However, in contrast to our
results, acute acetic acid-induced colitis has been described as being substantially
attenuated by L. reuteri R2LC (Fabia et al. 1993b). The discrepancy between these
two studies may exist because a less severe model was used in the earlier study, as
can be deduced from the fact that the acetic acid was rinsed off after the exposure, a
procedure not included in the present study.
There is some tentative evidence that the effects of probiotics are host-specific, and
for optimal results the probiotic should be derived from the host species (for review,
see Salminen et al. 1998). L. rhamnosus GG is of human origin, and therefore its
applicability to the rat can be questioned. L. reuteri R2LC, however, is of rat origin
and has been shown, in contrast to our results, to be efficient in experimental colitis
(Fabia et al. 1993b, Mao et al. 1996). Therefore, host-specifity or the lack of it,
although it might play some part, does not explain our results.     
In addition to the stimulation of the bifidobacteria growth, GOS stimulated the growth
of total bacteria growing on MRS medium. The effect on total bacteria, however, was
smaller than the effect on bifidobacteria growth. The non-specific actions on the
microbiota could possibly result from lactose, glucose and galactose, which
constituted up to 37% of the mixtures used. Of these, lactose is most probably
responsible for the non-specific actions, since adult rats have been reported to have
low levels of lactase expression and activity in their small intestine (Büller et al. 1989,
Peuhkuri et al. 1997).
It is possible that GOS (or other components of the mixtures used) may stimulate the
growth of some noxious species that could counteract the potential positive effects of
GOS. Previous studies, however, have not detected any increase in the colonic
levels of total aerobes, Bacteroides, Clostridium, Enterococcus, Enterobacteria,
Streptococcus or Staphylococcus following GOS administration (Ito et al. 1990,
Rowland & Tanaka 1993, Djouzi & Andrieux 1997), though this does not, obviously,
prove the absence of some specific noxious species that could be stimulated by
GOS.
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6.3 EFFECTS OF L. RHAMNOSUS GG ON INTESTINAL CELL
KINETICS
The rate of mitoses, as well as the number of crypt cells, increased in the intestine
after mono-association with L. rhamnosus GG. A similar change has been observed
in germ-free rats exposed to conventional flora for three days (Uribe et al. 1997). In
the same study a reduction in the number of villus cells was found, whereas in the
present study an increase in the number of cells was detected after mono-
association with L. rhamnosus GG. This indicates that some of the effects seen with
L. rhamnosus GG are not specific to that strain but would result from any bacteria
species given to germ-free rats. Future studies should perhaps include other bacteria
species with which to compare the effects of L. rhamnosus GG. A group of germ-free
rats associated with conventional flora for the same periods of time as the L.
rhamnosus GG mono-association, could, at least, be included.
The increase in the number of crypt cells was seen in different parts of the small and
the large intestine after mono-association with L. rhamnosus GG. Mono-association
of L. rhamnosus GG generally also led to shorter crypts throughout the length of the
intestine. The increased number of crypt cells was not followed by deeper crypts,
indicating that there was a reduction in the individual cell size. This reduction is
probably a co-phenomenon of increased cell production.
Components of the cell wall of Escherichia coli and the cytosol of L. acidophilus are
sources of epithelial cell mitogens (Olaya et al. 1998). In gram-negative bacteria the
mitogenic effects probably result from the presence of lipopolysaccharides, and in
the case of gram-positive bacteria, from lipoteichoic acid or peptidoglycan (Olaya et
al. 2001). The latter may be the mechanism behind the mitogenic effects of L.
rhamnosus GG seen in the present study.
The mitogenic effect of L. rhamnosus GG may have beneficial effects in intestinal
inflammation, since increased cell production contributes to enhanced mucosal
regeneration. Increased cell production could also act as a washout mechanism for
pathogenic microbial agents.
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6.4 EFFECTS OF CYS-LT-1 RECEPTOR BLOCKADE ON
EXPERIMENTAL COLITIS
Administration of a cys-LT-1 receptor blocker increased in vitro production of
prostaglandins in acute severe colitis induced by TNBS, but was ineffective in the
treatment of colonic inflammation. In mild colitis induced by DSS, in contrast, the
administration of the same blocker slightly reduced the colonic inflammation, possibly
by reducing the ratio of LTB4/ PGE2 production.
Although PGE2 production increased in the early phase of inflammation in the group
administered with the cys-LT-1 receptor blocker, COX-2 protein expression was not
affected. These two observations are not inconsistent with one another when the
different aspects they evaluate are taken into account: the tissue sample for PGE2
measurements was taken from the most intensively inflamed region, whereas an
entire colon length sample was taken for the COX-2 expression measurement. This
means that the former measures the ability of the affected area to produce PGE2,
whereas the latter measures longitudinally the area of the inflammatory lesions in the
colon. At the later stage of acute inflammatory reaction, the group administered with
the cys-LT-1 receptor blocker tended to have decreased COX-2 protein expression
without any change in PGE2 production. These findings may be explained by the
acutely enhanced PGE2 production by the cys-LT-1 receptor blockade, followed by
the cytoprotective actions of PGE2 in the colon which led to the reduction of the
inflammatory reaction detected by decreased COX-2 expression.
The mechanism behind increased PGE2 production by the cys-LT-1 receptor
blockade is not clear. Previous studies have shown an increase in prostaglandin
synthesis by cys-LT-1 receptor blockade in experimental colitis (Nishikawa et al.
1995) and in gastric damage with a clear reduction in the extent of haemorrhagic
damage (Wallace et al. 1988).
In the present study, no cysteinyl leukotriene production was observed in the severe
colitis model, and in the mild model, there was no increase in cysteinyl leukotriene
production. It is possible that an increase might have been seen in the severe model
if incubation had been extended to 24 hours, as it was in the mild model. However,
since in the mild DSS model some amelioration of the colitis was found with
montelukast, an effect other than that of the cys-LT-1 receptor blockade cannot be
ruled out.
Summary and conclusions
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7 SUMMARY AND CONCLUSIONS
The present study investigated the effects of the treatment of experimental colitis in
rats by affecting colonic microbiota and eicosanoids.
The main findings are as follows:
 L. rhamnosus GG and L. reuteri R2LC did not affect acute colitis induced by
acetic acid.
 
 Galacto-oligosaccharides stimulated bifidobacteria growth, but were not
effective in ameliorating colitis in an acute TNBS-induced model.
 
 After mono-association with L. rhamnosus GG, both the number of caecal and
colonic crypt cells and the rate of mitoses in the caecal crypts increased,
whereas the depth of the crypts decreased.
 
 Administration of the cys-LT-1 receptor antagonist montelukast increased the
in vitro production of PGE2, but was not effective in the treatment of acute
severe colitis in a TNBS-model.
 
 Administration of montelukast reduced the occult blood in the faeces/ gross
bleeding, maintained normal body weight gain and tended to decrease the
ratio of LTB4/ PGE2 production in the colon in vitro in mild colitis induced by
DSS.
In conclusion, L. rhamnosus GG increases the production of epithelial cells in rats
mono-associated with this strain. However, L. rhamnosus GG, as well as L. reuteri
R2LC and galacto-oligosaccharides, are not able to attenuate acute colitis in rats.
Administration of cys-LT-1 receptor antagonist montelukast increases PGE2
production in vitro, but does not reduce the damage in acute severe colitis in rats. In
a mild experimental colitis model, in contrast, montelukast administration has some
colitis ameliorating effects.
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